{
  "meta": {
    "title": "00365_Late_Night_Pyq_Inicet_Obg-2",
    "url": "https://brainandscalpel.vercel.app/00365-late-night-pyq-inicet-obg-2-edc3c8eb.html",
    "scrapedAt": "2025-11-29T18:10:38.906Z"
  },
  "questions": [
    {
      "id": 6018,
      "choices": [
        {
          "id": 24042,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sensory level is from T10 to L1</span></span></span></p>"
        },
        {
          "id": 24043,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uterine contractility is mediated by innervations from level T7 - T8</span></span></span></p>"
        },
        {
          "id": 24044,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the 1st stage of labor, pain is due to the fibers at level of T10 - L1</span></span></span></p>"
        },
        {
          "id": 24045,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In early labor, pain is usually because of the uterine contraction</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is incorrect regarding innervation of the uterus?&nbsp;</span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q8924184",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769362,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Uterine contractility is mediated by innervations from level T7 - T8</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The incorrect statement regarding the innervation of the uterus is option B. Uterine contractility is primarily mediated by hormonal mechanisms rather than by specific spinal innervations. Hormones such as estrogen, prostaglandins, and oxytocin play a significant role in inducing uterine contractions, while progesterone helps maintain uterine relaxation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sensory level is from T10 to L1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The sensory innervation of the uterus is indeed from spinal levels T10 to L1. These afferent fibers enter the spinal cord via the inferior hypogastric plexus and are responsible for transmitting sensory information from the uterus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. In the 1st stage of labor, pain is due to the fibers at level of T10 - L1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> During the 1st stage of labor, pain is mediated by spinal segments T10 to L1. This pain is due to the distension of the cervix and lower uterine segment, as well as the contraction of the uterus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. In early labor, pain is usually because of the uterine contraction:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> In early labor, pain is usually related to uterine contractions, which stimulate nociceptors in the genital tract and can cause discomfort and pain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uterine contractility is not mediated by innervations from spinal level T7 - T8; instead, it is primarily influenced by hormonal mechanisms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/27/untitled-242.jpg\" style=\"height:223px; width:500px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 500, DC Dutta&rsquo;s Textbook of Obstetrics, 8<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 24043,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6010,
      "choices": [
        {
          "id": 24010,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Echocardiography for cardiac disease</span></span></span></p>"
        },
        {
          "id": 24011,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urine analysis for bacteriuria</span></span></span></p>"
        },
        {
          "id": 24012,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blood sugar levels for GDM</span></span></span></p>"
        },
        {
          "id": 24013,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VDRL for syphilis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The following cost-effective investigations are routinely recommended in the screening of antenatal mothers except?&nbsp;</span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q4144623",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769359,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Echocardiography for cardiac disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Echocardiography for cardiac disease is not part of routine antenatal screening. While it is important for detecting cardiac conditions, echocardiography is typically performed only if there is a known or suspected cardiac disease. Routine screening for all antenatal mothers does not include echocardiography due to its cost and the specific indications required for its use.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Routine antenatal screening is designed to identify common conditions that may affect the health of the mother and baby. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Urine analysis for bacteriuriaUrine analysis for bacteriuria:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is routinely performed to detect asymptomatic bacteriuria, which, if left untreated, can lead to urinary tract infections and increase the risk of preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Blood sugar levels for GDM Blood sugar levels for GDM (Gestational Diabetes Mellitus):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Screening for GDM is essential to identify women who develop diabetes during pregnancy, which can affect both maternal and fetal health.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. VDRL for syphilis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The VDRL (Venereal Disease Research Laboratory) test is a screening tool for syphilis, a sexually transmitted infection that can have serious consequences for both the mother and the baby if left untreated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Routine antenatal screening does not include echocardiography for cardiac disease unless there is a known or suspected condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 110, DC Dutta&rsquo;s Textbook of Obstetrics, 8<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 24010,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5912,
      "choices": [
        {
          "id": 23618,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transverse perineal muscles</span></span></span></p>"
        },
        {
          "id": 23619,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obturator muscle</span></span></span></p>"
        },
        {
          "id": 23620,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bulbospongiosus</span></span></span></p>"
        },
        {
          "id": 23621,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transverse perineal branches of pudendal nerves</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following structures are cut in mediolateral episiotomy except?&nbsp;</span></span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q3562497",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769159,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Obturator muscle</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The obturator muscle is not cut in a mediolateral episiotomy. It is located deeper in the pelvis and is not involved in the incision made during this procedure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Structures cut in a mediolateral episiotomy:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Posterior vaginal wall mucosa</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Perineal muscles:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Superficial and deep transverse perineal muscles</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bulbospongiosus</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Part of levator ani</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Subcutaneous tissue and skin</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a mediolateral episiotomy, the following structures are typically cut to facilitate childbirth:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Transverse perineal muscles:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These include the superficial and deep transverse perineal muscles.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Bulbospongiosus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A muscle of the perineum that is also incised during the procedure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Transverse perineal branches of pudendal nerves:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These branches can be affected during the episiotomy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a mediolateral episiotomy, various perineal structures, including the posterior vaginal wall mucosa, superficial and deep transverse perineal muscles, bulbospongiosus, part of the levator ani, subcutaneous tissue, and skin, are incised. The obturator muscle is not involved in this procedure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition Pg 649</span></strong></span></span></p>",
      "correct_choice_id": 23619,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5818,
      "choices": [
        {
          "id": 23242,
          "text": "<p><span style=\"font-size:12pt;\">Continue warfarin throughout the pregnancy</span></p>"
        },
        {
          "id": 23243,
          "text": "<p><span style=\"font-size:12pt;\">Replace warfarin with heparin in first trimester</span></p>"
        },
        {
          "id": 23244,
          "text": "<p><span style=\"font-size:12pt;\">Give accoumarin</span></p>"
        },
        {
          "id": 23245,
          "text": "<p><span style=\"font-size:12pt;\">Use LMW heparin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A pregnant female with known cardiac disease presents in the first trimester with history of warfarin embryopathy. What should be advised now?&nbsp;</span>(INICET NOV 2018)</p>",
      "unique_key": "Q2513391",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769131,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Replace warfarin with heparin in first trimester</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Warfarin readily crosses the placenta and is associated with teratogenic effects, particularly when exposure occurs between the 6th and 9th weeks of pregnancy. Warfarin embryopathy is characterized by stippled epiphysis and nasal hypoplasia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Management guidelines for pregnant women with mechanical heart valves requiring anticoagulation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>First trimester:</strong> Women on warfarin should be switched to heparin as soon as pregnancy is diagnosed to avoid teratogenic effects.</span></li><li><span style=\"font-size:12pt;\"><strong>Second and third trimesters (13 to 36 weeks):</strong> Warfarin can be resumed as it is the most effective anticoagulant in preventing thromboembolic events.</span></li><li><span style=\"font-size:12pt;\"><strong>Near delivery:</strong> Warfarin should be switched back to heparin around delivery to avoid complications. Heparin should be stopped prior to delivery.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Mechanical heart valves:</strong> Require lifelong anticoagulation, whereas bioprosthetic valves do not require lifelong anticoagulation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Continue warfarin throughout the pregnancy:</strong> Continuing warfarin throughout the pregnancy is not advisable due to the risk of warfarin embryopathy and potential fetal hemorrhage.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Give accoumarin:</strong> Accoumarin is not a standard recommendation for anticoagulation in pregnant women with mechanical heart valves.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Use LMW heparin:</strong> While low molecular weight heparin (LMWH) is safer in pregnancy compared to warfarin, the specific recommendation is to switch to heparin in the first trimester and possibly back to warfarin in the second and third trimesters, depending on individual risk assessments.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In pregnant women with mechanical heart valves on warfarin, switch to heparin as soon as pregnancy is diagnosed in the first trimester to avoid teratogenic effects, and manage anticoagulation carefully throughout the pregnancy to minimize risks to both mother and fetus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/02/untitled-287.jpg\" alt=\"\" width=\"600\" height=\"667\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Algorithm for management of women with prosthetic heart valves requiring anti-coagulation in pregnancy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: William’s textbook of obstetrics 26<sup>th</sup> edition pg 2406</strong></span></p>",
      "correct_choice_id": 23243,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5907,
      "choices": [
        {
          "id": 23598,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medical management</span></span></span></p>"
        },
        {
          "id": 23599,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follow up with beta-hCG</span></span></span></p>"
        },
        {
          "id": 23600,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Suction and evacuation</span></span></span></p>"
        },
        {
          "id": 23601,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hysterectomy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with 12 weeks amenorrhea presents with vaginal bleeding. On examination, the cervical os is open and the uterus is 14 weeks size. USG shows a snowstorm appearance. The next best step in the management is?&nbsp;</span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q8136026",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769157,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Suction and evacuation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The snowstorm appearance on ultrasound is characteristic of a complete molar pregnancy (hydatidiform mole). Molar pregnancies are abnormal pregnancies where there is an overgrowth of trophoblastic tissue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key Points:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Complete Molar Pregnancy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Presents with vaginal bleeding, an enlarged uterus greater than expected for gestational age, and a snowstorm appearance on ultrasound.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The primary treatment for a molar pregnancy is suction and evacuation to remove the abnormal trophoblastic tissue.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post-Evacuation Surveillance:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> After evacuation, it is crucial to monitor beta-hCG levels to ensure complete removal of the molar tissue and to detect any possible malignancy (e.g., choriocarcinoma).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Medical management:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Medical management is not appropriate for molar pregnancy, as surgical evacuation is necessary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Follow up with beta-hCG:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Beta-hCG monitoring is essential after the initial treatment but not before the evacuation of the molar tissue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hysterectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hysterectomy is not the first line of treatment for a molar pregnancy unless there are specific complications or risk factors warranting such an invasive procedure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The management of a molar pregnancy involves suction and evacuation to remove the abnormal trophoblastic tissue, followed by post-evacuation surveillance with beta-hCG levels to monitor for persistent gestational trophoblastic disease or malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s Textbook of obstetrics 26<sup>th</sup> edition pg 614</span></strong></span></span></p>",
      "correct_choice_id": 23600,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5930,
      "choices": [
        {
          "id": 23690,
          "text": "<p><span style=\"font-size:12.0pt;\">8</span></p>"
        },
        {
          "id": 23691,
          "text": "<p><span style=\"font-size:12.0pt;\">5</span></p>"
        },
        {
          "id": 23692,
          "text": "<p><span style=\"font-size:12.0pt;\">3</span></p>"
        },
        {
          "id": 23693,
          "text": "<p><span style=\"font-size:12.0pt;\">0</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A primigravida is in labour. Her per-vaginal examination revealed a posterior cervix with 5 cm cervical length, 1 cm dilatation, soft consistency, and head at -1 station. Calculate the modified Bishop score?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q3203291",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769167,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) 5</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Bishop Score</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">This is a scoring system used to assess the favorability of the cervix to respond to induction of labor.&nbsp;</span></li><li><span style=\"font-size:12.0pt;\">A cervix that is soft in consistency, a little dilated, short in length, anteriorly placed and the station of the presenting low down will respond well to induction of labor.&nbsp;</span></li><li><span style=\"font-size:12.0pt;\">The Bishop score was replaced by the Modified Bishop score, wherein, the cervical effacement (in terms of percentage) was replaced by cervical length (in cm).&nbsp;</span></li><li><span style=\"font-size:12.0pt;\">The 5 components of the Modified Bishop score are:</span><ol style=\"list-style-type:decimal;\"><li><span style=\"font-size:12.0pt;\">Cervical Dilatation</span></li><li><span style=\"font-size:12.0pt;\">Cervical length</span></li><li><span style=\"font-size:12.0pt;\">Cervical consistency</span></li><li><span style=\"font-size:12.0pt;\">Cervical Position</span></li><li><span style=\"font-size:12.0pt;\">Station of the presenting part</span></li></ol></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Easy to remember Mnemonic</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">B – Bishop</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">I – Effacement</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">S – Station of presenting part</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">H – Hard/ soft (consistency)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">O – Os dilatation (cervical dilatation)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">P – Position of the cervix</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The scoring is as shown in the table.</span></li><li><span style=\"font-size:12.0pt;\">Each component is scored from 0 to 3</span></li><li><span style=\"font-size:12.0pt;\">The highest score is 13 and the lowest is 0</span></li><li><span style=\"font-size:12.0pt;\">A favourable score is &gt; 6. This means the patient will respond favorably to methods of induction of labor.&nbsp;</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/26/untitled-226_ZlB06tA.jpg\" alt=\"\" width=\"900\" height=\"473\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">The Modified Bishop score is used to assess the cervix's favorability for induction, and a score of 5 in this context would be based on specific factors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 600, DC Dutta’s Textbook of Obstetrics 8<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23691,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5925,
      "choices": [
        {
          "id": 23670,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Blighted ovum</span></span></span></p>"
        },
        {
          "id": 23671,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">﻿﻿﻿Missed abortion</span></span></span></p>"
        },
        {
          "id": 23672,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">﻿﻿﻿Ectopic pregnancy</span></span></span></p>"
        },
        {
          "id": 23673,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">﻿﻿﻿Hydatidiform mole</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A primigravida in her 10th week of gestation presents with spotting. On examination, the uterus corresponds to 12 weeks. Transvaginal ultrasound was done and it is given below. What is your diagnosis?&nbsp;</span></span>(INICET MAY 2021)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_Y739Z2T.jpg\" style=\"height:253px; width:300px\" /></span></span></span></span></p>",
      "unique_key": "Q2415847",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769164,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Hydatidiform mole</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The typical &lsquo;Snowstorm appearance&rsquo; on ultrasound is indicative of a hydatidiform mole. This appearance is characteristic of a complete molar pregnancy, where there is a proliferation of abnormal tissue instead of a viable embryo.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Complete Mole:</span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ultrasound Finding:</span></strong><span style=\"font-size:12.0pt\"> Snowstorm appearance with diffuse, heterogeneous echogenicity.</span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Genetics:</span></strong><span style=\"font-size:12.0pt\"> Diploid with only paternal genetic material. It can occur due to either:</span></span></span>\r\n\t\t<ul style=\"list-style-type:square\">\r\n\t\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">One sperm fertilizing an empty or inactivated ovum (androgenesis), leading to 46XX or 46XY.</span></span></span></li>\r\n\t\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Two sperm fertilizing an empty ovum (dispermy), also leading to 46XX or 46XY.</span></span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clinical Management:</span></strong><span style=\"font-size:12.0pt\"> Suction evacuation is the standard treatment.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Partial Mole:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Genetics:</span></strong><span style=\"font-size:12.0pt\"> Triploid, with 69XXX or 69XXY, resulting from two sperm fertilizing one ovum.</span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clinical Appearance:</span></strong><span style=\"font-size:12.0pt\"> Typically has a more complex presentation with an abnormal fetus.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Blighted ovum:</span></strong><span style=\"font-size:12.0pt\"> Also known as an anembryonic pregnancy, this occurs when a gestational sac forms but no embryo is visible. It does not present with the Snowstorm appearance and usually lacks the pronounced proliferation of tissue seen in a hydatidiform mole.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Missed abortion:</span></strong><span style=\"font-size:12.0pt\"> This involves the retention of an embryo or fetus with no detectable heartbeat or growth. The ultrasound findings typically show a non-viable fetus without the characteristic snowstorm pattern of a hydatidiform mole.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ectopic pregnancy:</span></strong><span style=\"font-size:12.0pt\"> This occurs when a fertilized egg implants outside the uterus, often in the fallopian tubes. It would not present with the Snowstorm appearance but rather show a gestational sac or products of conception in an abnormal location.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The &#39;Snowstorm appearance&#39; on transvaginal ultrasound is characteristic of a hydatidiform mole.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 225, DC Dutta&rsquo;s Textbook of Obstetrics 8<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23673,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5817,
      "choices": [
        {
          "id": 23238,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pelvic sonography</span></span></span></p>"
        },
        {
          "id": 23239,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hysterosalpingography</span></span></span></p>"
        },
        {
          "id": 23240,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial Biopsy</span></span></span></p>"
        },
        {
          "id": 23241,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Karyotyping of the parents</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female comes to Gynecology OPD for pre-conceptual counseling, with 2 prior second trimester abortions. What is the next investigation you will advise?&nbsp;</span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q9009396",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769130,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Pelvic sonography</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common cause of recurrent second trimester pregnancy loss (RPL) is anatomical abnormalities of the uterus. The initial investigation for anatomical abnormalities is a transvaginal ultrasound (pelvic sonography) as it is non-invasive and provides detailed imaging of the uterine structure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key Points:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrent first trimester abortions:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Often associated with antiphospholipid antibody syndrome (APLA) or endocrinological causes.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrent second trimester abortions:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Often associated with anatomical uterine problems.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Single spontaneous abortion:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Most commonly caused by fetal genetic abnormalities.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Hysterosalpingography:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is not routinely advised for anatomical abnormalities of the uterus. It is more commonly used for evaluating tubal patency and uterine cavity shape but is not the first-line investigation in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Endometrial Biopsy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is advised in women with suspected genital tuberculosis or in women with suspected luteal phase defect. It is not typically indicated for recurrent second trimester pregnancy loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Karyotyping of the parents:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Chromosomal abnormalities, such as balanced translocations, account for only about 5% of recurrent pregnancy loss (RPL). Therefore, parental karyotyping is not an initial investigation of choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The initial investigation for recurrent second trimester pregnancy loss (RPL) is pelvic sonography to evaluate for anatomical abnormalities of the uterus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 2<sup>t6h</sup> edition pg 203</span></strong></span></span></p>",
      "correct_choice_id": 23238,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5872,
      "choices": [
        {
          "id": 23458,
          "text": "<p><span style=\"font-size:12pt;\">Immediate C- section</span></p>"
        },
        {
          "id": 23459,
          "text": "<p><span style=\"font-size:12pt;\">Dexamethasone for fetal lung maturity</span></p>"
        },
        {
          "id": 23460,
          "text": "<p><span style=\"font-size:12pt;\">Induction - vaginal delivery</span></p>"
        },
        {
          "id": 23461,
          "text": "<p><span style=\"font-size:12pt;\">MgSO4 IV</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 33-week multigravida woman presents with epigastric pain, headache, visual symptoms, proteinuria: 3+. The next step of management would be?&nbsp;</span>(INICET NOV 2019)</p>",
      "unique_key": "Q6448978",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769145,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D) MgSO4 IV</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In the scenario of imminent eclampsia, neuro-prophylaxis with Magnesium Sulfate (MgSO4) is recommended. Imminent eclampsia is characterized by symptoms such as severe headaches, visual disturbances, epigastric pain, and hyperreflexia, indicating that the woman is at high risk of developing seizures (eclampsia). MgSO4 is effective in preventing seizures in women with severe pre-eclampsia and imminent eclampsia, as supported by the Magpie Trial, which is the largest comparative study demonstrating its efficacy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Magpie Trial (MgSO4 for Prevention of Eclampsia) showed that MgSO4 prophylaxis in women with severe pre-eclampsia effectively prevented the development of eclampsia, making it the standard of care for neuro-prophylaxis in such cases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Dexamethasone:</strong> Dexamethasone is an antenatal steroid used to enhance fetal lung maturation in pregnancies less than 34+6 weeks. It is administered in doses of 6 mg every 12 hours for a total of four doses. However, it is not used for neuro-prophylaxis in imminent eclampsia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Betamethasone:</strong> Betamethasone, like dexamethasone, is also an antenatal steroid given to enhance fetal lung maturation in pregnancies less than 34+6 weeks. The typical regimen is 12 mg administered 24 hours apart for two doses. It is not used for neuro-prophylaxis in imminent eclampsia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. LSCS:</strong> The mode of delivery, whether vaginal or Lower Segment Cesarean Section (LSCS), will depend on the status of the cervical os and other obstetric indications. LSCS is not a prophylactic measure for preventing eclampsia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">MgSO4 is recommended for neuro-prophylaxis in women with severe or imminent eclampsia to prevent seizures.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: William’s textbook of obstetrics 26<sup>th</sup> edition pg 1840</strong></span></p>",
      "correct_choice_id": 23461,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5814,
      "choices": [
        {
          "id": 23226,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wait and watch for 4 weeks</span></span></span></p>"
        },
        {
          "id": 23227,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Repeat TVS after one week</span></span></span></p>"
        },
        {
          "id": 23228,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum HCG levels</span></span></span></p>"
        },
        {
          "id": 23229,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medical intervention</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A lady with 7 weeks amenorrhea presented with slight vaginal spotting. Crown Rump Length was 5 mm with a well-formed gestational sac with a calculated gestational age of 5.6 weeks on TVS. What is the next line of management?&nbsp;</span></span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q7021997",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769127,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Repeat TVS after one week</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the case described, the patient has a gestational sac and a crown-rump length (CRL) of 5 mm, with a calculated gestational age of 5.6 weeks based on transvaginal sonography (TVS). The guidelines for assessing early pregnancy viability are:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absence of an embryo at a mean sac diameter (MSD) &ge; 25 mm indicates an anembryonic pregnancy.</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absence of cardiac activity at a CRL &ge; 7 mm indicates a non-viable pregnancy.</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this scenario, the CRL is 5 mm, which is below the threshold where the absence of cardiac activity would indicate a non-viable pregnancy (&ge; 7 mm). There is no mention of cardiac activity in the current ultrasound findings, so it is crucial to monitor the pregnancy further before making any conclusions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The best course of action is to repeat the transvaginal ultrasound after one week to check for the presence of cardiac activity and further development of the embryo.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This approach allows for a more accurate assessment of the viability of the pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Wait and watch for 4 weeks:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Waiting for 4 weeks without further evaluation could delay necessary medical intervention and is not recommended for timely assessment of pregnancy viability.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Serum HCG levels:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While measuring serum HCG levels can provide some information about the progression of the pregnancy, it is less specific than ultrasound for determining viability, particularly in the context of assessing cardiac activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Medical intervention:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Immediate medical intervention is not warranted at this stage without further evidence. The repeat ultrasound will provide more clarity on whether intervention is needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In early pregnancy with a CRL of less than 7 mm and no documented cardiac activity, the best approach is to repeat the transvaginal ultrasound after one week to reassess for the presence of cardiac activity and viability of the pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition pg 645</span></strong></span></span></p>",
      "correct_choice_id": 23227,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5954,
      "choices": [
        {
          "id": 23786,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Clindamycin</span></span></span></p>"
        },
        {
          "id": 23787,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">﻿﻿Metronidazole</span></span></span></p>"
        },
        {
          "id": 23788,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cotrimoxazole</span></span></span></p>"
        },
        {
          "id": 23789,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Azithromycin</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old female presents with complaints of foul-smelling vaginal discharge. Drug of choice to treat this condition is?&nbsp;</span></span>(INICET MAY 2021)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_KhxwfGV.jpg\" style=\"height:299px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q6774384",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769349,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Metronidazole</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with foul-smelling vaginal discharge, which is a common symptom of bacterial vaginosis (BV). In bacterial vaginosis, the correct treatment is <strong>Metronidazole</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Bacterial vaginosis</span></strong><span style=\"font-size:12.0pt\"> is often caused by an imbalance in the normal bacterial flora of the vagina, commonly involving Gardnerella vaginalis. The condition is diagnosed using Amsel&#39;s Criteria, which include:</span></span></span>\r\n\r\n\t<ol>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Thin, white homogenous vaginal discharge</span></strong><span style=\"font-size:12.0pt\">: The discharge is typically thin and white, and may have a fishy odor.</span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">pH of Vaginal fluid &gt; 4.5</span></strong><span style=\"font-size:12.0pt\">: This elevated pH level is higher than the normal acidic environment of the vagina.</span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Fishy odor of discharge on adding 10% KOH (Whiff test)</span></strong><span style=\"font-size:12.0pt\">: The discharge develops a characteristic fishy odor when mixed with potassium hydroxide.</span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Presence of Clue cells on microscopy</span></strong><span style=\"font-size:12.0pt\">: Clue cells are vaginal epithelial cells that have a stippled appearance due to adherence of bacteria.</span></span></span></li>\r\n\t</ol>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metronidazole is the first-line treatment for bacterial vaginosis, and it is typically administered as oral tablets (500 mg twice daily for 7 days).</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Clindamycin</span></strong><span style=\"font-size:12.0pt\">: While Clindamycin can be used to treat bacterial vaginosis, it is generally not the first choice. Metronidazole is preferred due to its effectiveness and established use.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cotrimoxazole</span></strong><span style=\"font-size:12.0pt\">: This antibiotic is used for a variety of bacterial infections but is not effective for bacterial vaginosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Azithromycin</span></strong><span style=\"font-size:12.0pt\">: This is a macrolide antibiotic used primarily for sexually transmitted infections such as chlamydia and is not used for bacterial vaginosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The drug of choice for treating bacterial vaginosis is Metronidazole.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 554, DC Dutta&rsquo;s Textbook of gynecology 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23787,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5901,
      "choices": [
        {
          "id": 23574,
          "text": "<p><span style=\"font-size:12pt;\">Serum progesterone on day 14</span></p>"
        },
        {
          "id": 23575,
          "text": "<p><span style=\"font-size:12pt;\">Serum progesterone on day 21</span></p>"
        },
        {
          "id": 23576,
          "text": "<p><span style=\"font-size:12pt;\">Serum LH on day 14</span></p>"
        },
        {
          "id": 23577,
          "text": "<p><span style=\"font-size:12pt;\">Serum LH on day 21</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 30-year-old woman visits an infertility clinic. She has a regular 28-day cycle. How should she be evaluated?&nbsp;</span>(INICET NOV 2020)</p>",
      "unique_key": "Q2951263",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769155,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Serum progesterone on day 21</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">For a woman with a regular 28-day cycle, serum progesterone is typically measured on day 21 to assess for ovulation. Progesterone levels on day 21 of the menstrual cycle provide information about whether ovulation has occurred.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Key Points:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Day 21 Progesterone Measurement:</strong> In a regular 28-day cycle, day 21 corresponds to the mid-luteal phase, about 7 days after ovulation. Progesterone levels peak during this time, and values above 10 ng/mL are indicative of ovulation.</span></li><li><span style=\"font-size:12pt;\"><strong>Purpose:</strong> This test helps to determine if the cycles are ovulatory or anovulatory.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other tests for ovulation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Basal body temperature:</strong> A biphasic temperature pattern suggests ovulation.</span></li><li><span style=\"font-size:12pt;\"><strong>Urinary LH kits (ovulation prediction kits):</strong> Ovulation occurs the day following the peak LH surge.</span></li><li><span style=\"font-size:12pt;\"><strong>Endometrial biopsy:</strong> This can provide histological confirmation of ovulation.</span></li><li><span style=\"font-size:12pt;\"><strong>Ultrasonography:</strong> Follicular tracking can visualize the growth and rupture of the follicle.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Serum progesterone on day 14:</strong> Measuring progesterone on day 14 is not useful as it corresponds to the follicular phase when progesterone levels are low and not indicative of ovulation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Serum LH on day 14:</strong> While an LH surge around day 14 can indicate impending ovulation, it does not confirm that ovulation has actually occurred.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Serum LH on day 21:</strong> Measuring LH on day 21 is not useful for assessing ovulation, as LH levels peak around mid-cycle and are not elevated during the luteal phase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">For a woman with a regular 28-day menstrual cycle, measuring serum progesterone on day 21 is the appropriate method to evaluate for ovulation, with levels above 10 ng/mL indicating that ovulation has occurred.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Williams Textbook of gynecology 3<sup>rd</sup> edition Pg435</strong></span></p>",
      "correct_choice_id": 23575,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5816,
      "choices": [
        {
          "id": 23234,
          "text": "<p><span style=\"font-size:12pt;\">Radical vulvectomy with unilateral LN dissection</span></p>"
        },
        {
          "id": 23235,
          "text": "<p><span style=\"font-size:12pt;\">Radical vulvectomy with bilateral LN dissection</span></p>"
        },
        {
          "id": 23236,
          "text": "<p><span style=\"font-size:12pt;\">Simple vulvectomy</span></p>"
        },
        {
          "id": 23237,
          "text": "<p><span style=\"font-size:12pt;\">Chemoradiation with resection</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 76-year-old female presented with a non-healing ulcer on the labia majora for a period of 6 months, measuring 2 cm x 3 cm. No lymph nodes were palpable. Biopsy shows squamous cell carcinoma. How do you manage this case?&nbsp;</span>(INICET NOV 2018)</p>",
      "unique_key": "Q2514297",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769129,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Radical vulvectomy with bilateral LN dissection</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">This patient has a midline lesion on the labia majora, which indicates that the lesion is close to or crossing the midline. In cases of midline lesions or lesions within 2 cm of the midline, bilateral inguinofemoral lymph node dissection is necessary along with radical vulvectomy. This approach ensures that all potential pathways of lymphatic spread are adequately addressed.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>New (2021) FIGO staging for carcinoma of the vulva:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Tumors 2 cm or less in size with 1 mm or less invasion:</strong> Treated by wide local excision.</span></li><li><span style=\"font-size:12pt;\"><strong>Tumors more than 2 cm with more than 1 mm depth of invasion:</strong> Treated by modified radical vulvectomy with groin lymph node dissection.</span></li><li><span style=\"font-size:12pt;\"><strong>LN dissection through separate incision:</strong> Lymph node dissection should be inguino-femoral.</span></li><li><span style=\"font-size:12pt;\"><strong>Bilateral lymph node dissection:</strong> Performed for midline lesions and those within 2 cm of the midline.</span></li><li><span style=\"font-size:12pt;\"><strong>Unilateral dissection:</strong> If the lesion is unilateral and ipsilateral nodes are negative, bilateral dissection is not necessary.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Radical vulvectomy with unilateral LN dissection:</strong> This would be appropriate for unilateral lesions with no evidence of contralateral spread, but not for midline lesions.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Simple vulvectomy:</strong> Simple vulvectomy is not sufficient for managing invasive squamous cell carcinoma with a lesion size of 2 cm x 3 cm and potential for deeper invasion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Chemoradiation with resection:</strong> Chemoradiation followed by resection is typically reserved for advanced or inoperable cases, or where there is a need to downstage the tumor before surgery. This case can be managed surgically given the size and lack of palpable lymph nodes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">For midline lesions or lesions within 2 cm of the midline in squamous cell carcinoma of the vulva, radical vulvectomy with bilateral inguinofemoral lymph node dissection is the appropriate management.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: FIGO staging of CA vulva, Berek and Novak’s gynecology 15<sup>th</sup> edition pg 1436, William’s textbook of gynecology 3rd edition pg 484-485.</strong></span></p>",
      "correct_choice_id": 23235,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6003,
      "choices": [
        {
          "id": 23982,
          "text": "<p><span style=\"font-size:12pt;\">Includes breathing, movements, tone, and </span><span style=\"font-size:12.0pt;\">Amniotic fluid volume&nbsp;</span></p>"
        },
        {
          "id": 23983,
          "text": "<p><span style=\"font-size:12pt;\">Can tell us about fetal outcome and fetal pH</span></p>"
        },
        {
          "id": 23984,
          "text": "<p><span style=\"font-size:12pt;\">Score is inconsistent with fetal pH at different gestational ages</span></p>"
        },
        {
          "id": 23985,
          "text": "<p><span style=\"font-size:12pt;\">Score &lt;4: fetal pH &lt;7.2; Score 0: 100% fetal acidemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All are true about biophysical profile (BPP) except?&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q9495407",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769353,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) Score is inconsistent with fetal pH at different gestational ages</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12pt;\">BPP score is not inconsistent with fetal pH, but has a direct linear relationship with fetal pH and thus can be used to predict fetal acidemia.</span></li><li><span style=\"font-size:12pt;\">BPP is a multi-parametric, screening test to assess uteroplacental insufficiency.</span></li><li><span style=\"font-size:12pt;\">It consists of five components/ variables and the observations are made in a 30 minutes time period.</span></li><li><span style=\"font-size:12pt;\">The Biophysical Profile has 5 components and is scored using Manning score</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">NST</span></li><li><span style=\"font-size:12pt;\">Amniotic Fluid Volume</span></li><li><span style=\"font-size:12pt;\">Fetal movement</span></li><li><span style=\"font-size:12pt;\">Fetal Tone</span></li><li><span style=\"font-size:12pt;\">Fetal Breathing</span></li></ul></li></ul><p>&nbsp;&nbsp;&nbsp; <img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/06/screenshot-2024-08-06-171706.png\" alt=\"\" width=\"1000\" height=\"481\"></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">A low Manning score correlates with fetal hypoxia</span></li><li><span style=\"font-size:12pt;\">Narcotics and sedatives can significantly lower the score</span></li><li><span style=\"font-size:12pt;\">A BPP score of 0 was almost invariably associated with significant fetal acidemia, whereas a normal score of 8 or 10 was associated with normal pH.</span></li><li><span style=\"font-size:12pt;\">An equivocal test result—a score of 6—was a poor predictor of an abnormal outcome. A drop in the BPP score from 2 or 4 down to 0 more accurately predicted an abnormal fetal outcome.</span></li><li><span style=\"font-size:12pt;\">Overall, BPP scores provided poor sensitivity to predict cord blood pH</span></li><li><span style=\"font-size:12pt;\">The Modified BPP has 2 components</span><ul><li><span style=\"font-size:12pt;\">NST</span></li><li><span style=\"font-size:12pt;\">AFI</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Includes breathing, movements, tone, and </strong></span><span style=\"font-size:12.0pt;\"><strong>Amniotic fluid volume</strong></span><span style=\"font-size:12pt;\"><strong>: </strong>This statement is true. The BPP includes assessments of fetal breathing, movements, tone, and the </span><span style=\"font-size:12.0pt;\">Amniotic fluid volume&nbsp;</span><span style=\"font-size:12pt;\">as part of its evaluation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Can tell us about fetal outcome and fetal pH</strong>: This statement is true. The BPP score helps predict fetal outcome and provides an indication of fetal pH, reflecting the level of fetal distress.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Score &lt;4: fetal pH &lt;7.2; Score 0: 100% fetal acidemia</strong>: This statement is true. A BPP score of less than 4 correlates with a fetal pH &lt;7.2, and a score of 0 is almost invariably associated with significant fetal acidemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Biophysical Profile (BPP) provides a consistent prediction of fetal pH and outcome, with a lower score correlating with increased risk of fetal acidemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 999, Williams Obstetric 26<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23984,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5812,
      "choices": [
        {
          "id": 23218,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milky to yellowish green with mucus flakes</span></span></span></p>"
        },
        {
          "id": 23219,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amber colored</span></span></span></p>"
        },
        {
          "id": 23220,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clear colorless to pale yellow</span></span></span></p>"
        },
        {
          "id": 23221,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Golden color</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following are the features of the color of normal amniotic fluid during?&nbsp;</span></span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q4772012",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769125,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Clear colorless to pale yellow</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The color of normal amniotic fluid varies during pregnancy and can indicate different conditions:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In early pregnancy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The amniotic fluid is colorless.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Near term:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It becomes straw-colored.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deep yellow/golden color:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This can indicate fetal anemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Green (meconium-stained):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Indicates fetal distress or post-maturity.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Red:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Suggests abruption.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dark colored/tobacco-like:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Indicates fetal demise.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal amniotic fluid should be clear, colorless, or pale yellow, especially in the earlier stages of pregnancy and near term when the fluid changes to a straw color.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Milky to yellowish green with mucus flakes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This description is not characteristic of normal amniotic fluid. Such a color can indicate the presence of infection or contamination.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amber colored:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amber-colored amniotic fluid is not a normal finding and may indicate complications such as the presence of blood or other abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Golden color:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Golden-colored amniotic fluid typically indicates fetal anemia, which is a pathological condition and not a feature of normal amniotic fluid.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal amniotic fluid is clear, colorless to pale yellow, changing to straw-colored near term.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of obstetrics 8th edition Pg 43, William&rsquo;s text book of obstetrics 24th edition pg 298</span></strong></span></span></p>",
      "correct_choice_id": 23220,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5933,
      "choices": [
        {
          "id": 23702,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">2 doses of 6 mg given 12 hours apart</span></span></span></p>"
        },
        {
          "id": 23703,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">2 doses of 12 mg given 24 hours apart</span></span></span></p>"
        },
        {
          "id": 23704,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">4 doses of 6 mg given 12 hours apart</span></span></span></p>"
        },
        {
          "id": 23705,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">4 doses of 12 mg given 12 hours apart</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the dose of dexamethasone given for fetal lung maturity?&nbsp;</span></span>(INICET MAY 2021)</p>",
      "unique_key": "Q6511157",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769339,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) 4 doses of 6 mg given 12 hours apart</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For fetal lung maturity, dexamethasone is administered to help reduce the risks associated with premature birth by promoting the development of the fetal lungs. The recommended regimen for dexamethasone is:</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">4 doses of 6 mg each&nbsp;</span></strong><span style=\"font-size:12.0pt\">administered intramuscularly every <strong>12 hours</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This dosing schedule is intended to maximize the benefit of corticosteroids in promoting fetal lung maturity and reducing the incidence of complications associated with preterm birth, such as respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and the need for ventilatory support.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 2 doses of 6 mg given 12 hours apart:</span></strong><span style=\"font-size:12.0pt\"> Incorrect. This dosing regimen is not the standard for dexamethasone. The correct regimen involves 4 doses of 6 mg.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 2 doses of 12 mg given 24 hours apart:</span></strong><span style=\"font-size:12.0pt\"> Incorrect. This regimen is used for betamethasone, not dexamethasone. The standard for dexamethasone is 4 doses of 6 mg.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 4 doses of 12 mg given 12 hours apart:</span></strong><span style=\"font-size:12.0pt\"> Incorrect. The correct dosing for dexamethasone is 6 mg per dose, not 12 mg.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For fetal lung maturity, the recommended dose of dexamethasone is 4 doses of 6 mg given intramuscularly every 12 hours.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 2088, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23704,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5821,
      "choices": [
        {
          "id": 23254,
          "text": "<p><span style=\"font-size:16px;\">Androgen insensitivity syndrome</span></p>"
        },
        {
          "id": 23255,
          "text": "<p><span style=\"font-size:16px;\">Turner syndrome</span></p>"
        },
        {
          "id": 23256,
          "text": "<p><span style=\"font-size:16px;\">True hermaphrodite</span></p>"
        },
        {
          "id": 23257,
          "text": "<p><span style=\"font-size:16px;\">Swyer's syndrome</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">A 20-year-old girl presents with primary amenorrhea. On examination breasts were found to be poorly developed, vagina was present. Ultrasound revealed a normal uterus, but gonads weren't detected. Further evaluation done showed 46XY karyotype. The most probable diagnosis?&nbsp;(INICET NOV 2018)</span></p>",
      "unique_key": "Q1278419",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769134,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. D) Swyer's syndrome</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The clinical scenario described is indicative of Swyer syndrome, which is characterized by a 46XY karyotype and gonadal dysgenesis.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Key points about Swyer syndrome:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:16px;\">Swyer syndrome, also known as 46XY gonadal dysgenesis, is a condition where individuals with an XY karyotype present phenotypically as females.</span></li><li><span style=\"font-size:16px;\">These patients have a normal uterus and vagina but lack functioning gonads, which are often termed \"streak gonads.\"</span></li><li><span style=\"font-size:16px;\">Because of gonadal dysgenesis, these individuals do not secrete testosterone or Antimullerian Hormone (AMH), leading to the development of female genital organs and phenotype.</span></li><li><span style=\"font-size:16px;\">Clinical presentation includes primary amenorrhea, absence of secondary sexual characteristics, and female external genitalia despite a 46XY karyotype.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Androgen insensitivity syndrome:</strong> Also known as testicular feminization syndrome, individuals have a 46XY karyotype but are phenotypically female with well-developed breasts and absent axillary and pubic hair. The gonads are testes, and there is no uterus.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Turner syndrome:</strong> Turner syndrome is characterized by a 45XO karyotype. Patients typically present with short stature, shield chest, cubitus valgus, poorly developed secondary sexual characteristics, and streak ovaries.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. True hermaphrodite:</strong> True hermaphrodites have both ovarian and testicular tissue present, which is not consistent with the clinical scenario described.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Swyer syndrome (46XY gonadal dysgenesis) is a condition where individuals with a 46XY karyotype present phenotypically as females with primary amenorrhea, poorly developed secondary sexual characteristics, and a normal uterus but lack functioning gonads.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Ref: Dutta’s textbook of gynecology 6<sup>th</sup> edition pg 33446, Williams textbook of gynecology 3<sup>rd</sup> edition pg373</strong></span></p>",
      "correct_choice_id": 23257,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5813,
      "choices": [
        {
          "id": 23222,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Twin to Twin Transfusion Syndrome</span></span></span></p>"
        },
        {
          "id": 23223,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Monochorionic diamniotic pregnancy</span></span></span></p>"
        },
        {
          "id": 23224,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Monochorionic monoamniotic pregnancy</span></span></span></p>"
        },
        {
          "id": 23225,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Dichorionic diamniotic pregnancy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify this condition?&nbsp;</span></span>(INICET NOV 2018)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_QSiuVik.jpg\" style=\"height:233px; width:250px\" /></span></span></span></p>",
      "unique_key": "Q5800499",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769126,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Monochorionic monoamniotic pregnancy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image shows a monochorionic monoamniotic placenta, characterized by a single placenta with two umbilical cords and no intervening membrane. Monochorionic monoamniotic twins share both a chorion and an amniotic sac. This type of twinning occurs when the inner cell mass divides between days 8 to 12 of gestation, after the formation of the trophoblast, leading to a monochorionic condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monochorionic monoamniotic twin gestations have a high fetal death rate due to several complications:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preterm birth</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital anomalies</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low birth weight</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cord entanglement</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The best time for delivery of monochorionic monoamniotic twins is between 32-34 weeks via Caesarean section.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Twin to Twin Transfusion Syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a complication seen in monochorionic twin pregnancies. It involves a donor twin and a recipient twin. The donor twin is anemic, growth-restricted, and has oligohydramnios, while the recipient twin is polycythemic, has polyhydramnios, and suffers from circulatory overload.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Monochorionic diamniotic pregnancy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> In this type of pregnancy, there are two amniotic cavities and one chorion. This occurs when the inner cell mass divides between 4-7 days of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Dichorionic diamniotic pregnancy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This pregnancy type involves two amniotic cavities and two chorions. It occurs when the inner cell mass divides between 0-3 days of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monochorionic monoamniotic pregnancies involve a single placenta with two umbilical cords and no intervening membrane, occurring when the inner cell mass divides between days 8 to 12 of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of Obstetrics 8th edition pg 233-234, </span></strong></span></span></p>",
      "correct_choice_id": 23224,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5837,
      "choices": [
        {
          "id": 23318,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amniocentesis</span></span></span></p>"
        },
        {
          "id": 23319,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿MCA doppler</span></span></span></p>"
        },
        {
          "id": 23320,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Cardiotocography</span></span></span></p>"
        },
        {
          "id": 23321,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Amniotic fluid index determination</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the procedure done in the labor room?&nbsp;</span></span>(INICET NOV 2018)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_ttNZkYp.jpg\" style=\"height:189px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q2013437",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769138,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Cardiotocography</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image shows a procedure called Cardiotocography (CTG). CTG is a method used to monitor the fetal heart rate (FHR) and uterine contractions during pregnancy and labor. It helps assess the well-being of the fetus and identify any signs of fetal distress.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key points about Cardiotocography (CTG):</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If done antenatally (when the patient is not in labor), it is called a Non-Stress Test (NST).</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During labor, CTG is used to continuously monitor the fetal heart rate and contractions to ensure the fetus is not in distress.</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Amniocentesis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amniocentesis is an invasive procedure in which a sample of amniotic fluid is aspirated for prenatal diagnosis or therapeutic purposes. This is not the procedure shown in the image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. MCA Doppler:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> MCA (Middle Cerebral Artery) Doppler is performed to assess fetal growth restriction and fetal anemia. It is an ultrasound procedure and does not match the image shown.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Amniotic Fluid Index (AFI):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> AFI is an ultrasound estimation of amniotic fluid volume. It is not depicted in the image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiotocography (CTG) is used to monitor the fetal heart rate and uterine contractions during pregnancy and labor. When performed antenatally without labor, it is referred to as a Non-Stress Test (NST).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 24<sup>th</sup> edition pg339, Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg122</span></strong></span></span></p>",
      "correct_choice_id": 23320,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5926,
      "choices": [
        {
          "id": 23674,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pap smear</span></span></span></p>"
        },
        {
          "id": 23675,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Visual inspection with iodine</span></span></span></p>"
        },
        {
          "id": 23676,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Colposcopy</span></span></span></p>"
        },
        {
          "id": 23677,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Endometrial sampling</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old patient with a history of diabetes and hypertension came with post-menopausal bleeding. Which of the following you will do to evaluate the cause?&nbsp;</span></span>(INICET MAY 2021)</p>",
      "unique_key": "Q2798438",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769165,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Endometrial sampling</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Endometrial sampling is done to evaluate a patient presenting with postmenopausal bleeding.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Transvaginal ultrasound (TVS) is a better first-line investigation since TVS is not included in the options, endometrial sampling is the next best answer.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Both diabetes and hypertension are risk factors for endometrial hyperplasia and carcinoma hence endometrial sampling would be the more appropriate test as compared to tests for cervical cancer screening.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Endometrial sampling is indicated in a woman with post-menopausal bleeding with the endometrial thickness is &gt; 4 mm. </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pap smear</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: A pap smear should be done in all women complaining of post menopausal women with a normal looking cervix and a cervical biopsy for all women with a cervical growth but in this question, based on risk factors, we are more worried about endometrial cancer and hence endometrial sampling is a better option. </span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Visual inspection with iodine</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This is not the preferred option and even if cervical cancer screening is warranted, a pap smear or HPV is better. </span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Colposcopy</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This is indicated if there is any cytological abnormality on the pap smear</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Endometrial sampling is done to evaluate a patient presenting with postmenopausal bleeding.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 560, DC Dutta&rsquo;s Textbook of Gynecology 6<sup>th</sup> edition.</span></strong></span></span></p>",
      "correct_choice_id": 23677,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5811,
      "choices": [
        {
          "id": 23214,
          "text": "<p><span style=\"font-size:12pt;\">Episiotomy scissors</span></p>"
        },
        {
          "id": 23215,
          "text": "<p><span style=\"font-size:12pt;\">﻿﻿﻿Curved artery</span></p>"
        },
        {
          "id": 23216,
          "text": "<p><span style=\"font-size:12pt;\">Curve Mayo scissor</span></p>"
        },
        {
          "id": 23217,
          "text": "<p><span style=\"font-size:12pt;\">﻿﻿﻿Mosquito forceps</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the instrument:&nbsp;(INICET NOV 2018)</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_S2GYht4.jpg\" alt=\"\" width=\"300\" height=\"159\"></span></p>",
      "unique_key": "Q2601543",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769124,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Episiotomy scissors</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">The instrument given in the picture is an episiotomy scissors.</span></li><li><span style=\"font-size:12pt;\">The angulation in the scissor is to prevent extension of pelvic tear into the anal margins and obstetric anal sphincter injuries / complete perineal tear.</span></li><li><span style=\"font-size:12pt;\">An episiotomy is NOT given routinely.</span></li><li><span style=\"font-size:12pt;\">It’s use is restricted and is given in situations like.</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Macrosomia</span></li><li><span style=\"font-size:12pt;\">After coming head of breech</span></li><li><span style=\"font-size:12pt;\">Instrumental delivery</span></li><li><span style=\"font-size:12pt;\">Shoulder dystocia</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Curved artery</strong>: It has serrated tips and ratchet lock . It is used to clamp blood vessels, hold peritoneal edges, tissue dissection</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/02/untitled-283.jpg\" alt=\"\" width=\"300\" height=\"179\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;<strong>Curved mayo scissors</strong>: These are used to cut tissue such as the uterus, rectus sheath etc.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/02/untitled-284.jpg\" alt=\"\" width=\"300\" height=\"93\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Mosquito forceps</strong>: It is a small artery forceps used to catch small bleeders.</span></p><p>&nbsp;</p><p><i><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/02/untitled-285.jpg\" alt=\"\" width=\"300\" height=\"169\"></i></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Episiotomy scissors are specifically designed with an angulated blade to prevent the extension of pelvic tears into the anal margins, thereby reducing the risk of obstetric anal sphincter injuries and complete perineal tears during childbirth.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Dutta textbook of obstetrics 8th edition pg 755</strong></span></p>",
      "correct_choice_id": 23214,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ImageBased",
        "InstrumentsBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6005,
      "choices": [
        {
          "id": 23990,
          "text": "<p><span style=\"font-size:12pt;\">Immunosuppression can be continued during pregnancy</span></p>"
        },
        {
          "id": 23991,
          "text": "<p><span style=\"font-size:12pt;\">Pregnancy to be planned once the disease has been quiescent for at least 6 months and there is no evidence of renal dysfunction</span></p>"
        },
        {
          "id": 23992,
          "text": "<p><span style=\"font-size:12pt;\">High dose corticosteroids for lupus flare in pregnancy is safe</span></p>"
        },
        {
          "id": 23993,
          "text": "<p><span style=\"font-size:12pt;\">Ecospirin, methotrexate, cyclophosphamide, corticosteroids, azathioprine are safe in pregnancy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Which of the following is not true about lupus nephritis in pregnancy?&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q3092800",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769354,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D) Ecospirin, methotrexate, cyclophosphamide, corticosteroids, azathioprine are safe in pregnancy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">SLE is a chronic autoimmune disorder involving the multisystem. It affects young women of childbearing age. The renal involvement of the disease can manifest in the form of active lupus nephritis or flare-ups during pregnancy.</span></li><li><span style=\"font-size:12pt;\">It can lead to preterm births, preeclampsia, and pregnancy loss while the infant can suffer from neonatal lupus and heart block.</span></li><li><span style=\"font-size:12pt;\">Management includes</span></li><li><span style=\"font-size:12pt;\">Preconceptionally counseling: Conception during a period of quiescence for at least 6 months determines a successful outcome. Stable remission of renal disease for at least 6 months before conception is recommended.</span></li><li><span style=\"font-size:12pt;\">Corticosteroids are useful during episodes of lupus flare and can be used safely in pregnancy.</span></li><li><span style=\"font-size:12pt;\">Immunosuppressants such as azathioprine can be continued during pregnancy. It may be used in case of severe SLE</span></li><li><span style=\"font-size:12pt;\">Hydroxychloroquine is found to be the best for maintenance and is safe in pregnancy. It can prevent the need for prolonged corticosteroid therapy.</span></li><li><span style=\"font-size:12pt;\">Methotrexate and cyclophosphamide are teratogenic and hence they are not safe during pregnancy.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Immunosuppression can be continued during pregnancy</strong>: Correct. Medications like azathioprine can be continued under medical guidance, while others are used cautiously.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Pregnancy to be planned once the disease has been quiescent for at least 6 months and there is no evidence of renal dysfunction</strong>: Correct. Quiescence of the disease and stable renal function are crucial for a successful pregnancy outcome.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. High dose corticosteroids for lupus flare in pregnancy is safe</strong>: Correct. High doses of corticosteroids can be used during a lupus flare, but must be carefully monitored.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Methotrexate and cyclophosphamide are not safe during pregnancy for managing lupus nephritis; corticosteroids and azathioprine are safer options.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page 2895, Williams Obstetrics 26<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23993,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5876,
      "choices": [
        {
          "id": 23474,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">6 to 10 weeks</span></span></span></p>"
        },
        {
          "id": 23475,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8 to 12 weeks</span></span></span></p>"
        },
        {
          "id": 23476,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">13 to 20 weeks</span></span></span></p>"
        },
        {
          "id": 23477,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20 to 28 weeks</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The risk of fetal varicella syndrome is maximum when the mother is infected between:&nbsp;</span></span>(INICET NOV 2019)</p>",
      "unique_key": "Q1066006",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769148,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 13 to 20 weeks</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Varicella Zoster Virus (VZV) is a double-stranded DNA virus that is primarily acquired in childhood and causes chickenpox. The virus is transmitted through direct contact with an infected individual. Nonimmune pregnant women who come into close contact with a patient with chickenpox are at risk of contracting the infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If a pregnant woman contracts chickenpox, particularly early in pregnancy, there is a risk of congenital varicella syndrome in the fetus. The highest risk period for the development of congenital varicella syndrome is between 13 and 20 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital varicella syndrome includes the following features:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chorioretinitis</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Microphthalmia</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cerebral cortical atrophy</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal growth restriction</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydronephrosis</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Limb hypoplasia</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cicatricial skin lesions</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If the fetus or neonate is exposed to active VZV infection just before or during delivery (less than 5 days before and up to 2 days after delivery), there is a significant risk of disseminated disease and CNS involvement in the neonate, with a mortality rate of approximately 30%. In such cases, administration of VZIG (Varicella-Zoster Immune Globulin) is recommended.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The highest risk period for the development of congenital varicella syndrome in a fetus is when the mother is infected with Varicella Zoster Virus between 13 and 20 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition pg 3085</span></strong></span></span></p>",
      "correct_choice_id": 23476,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6008,
      "choices": [
        {
          "id": 24002,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2, 3, 4 and 5</span></span></span></p>"
        },
        {
          "id": 24003,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2 and 5</span></span></span></p>"
        },
        {
          "id": 24004,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2, 3, 4 and 5</span></span></span></p>"
        },
        {
          "id": 24005,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 3 and 5</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A couple already has 3 children and has been trying for another one for the last 1 year. However, the husband is diagnosed with hypogonadotropic hypogonadism. Which of the following is/are true?&nbsp;</span></span></span>(INICET MAY 2022)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low FSH, low LH</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High FSH, low LH</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligospermia</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low prolactin</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low testosterone</span></span></span></li>\r\n</ol>",
      "unique_key": "Q7270098",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769357,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) 1, 3 and 5 </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypogonadotropic hypogonadism is a condition where there is decreased production of gonadotropins (FSH and LH) by the pituitary gland, leading to decreased stimulation of the testes and consequent reduced production of sex hormones such as testosterone. This results in:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1. Low FSH, low LH:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> In hypogonadotropic hypogonadism, both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are low due to inadequate stimulation from the pituitary gland.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3. Oligospermia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Reduced levels of FSH and LH lead to decreased stimulation of the testes, which can result in reduced sperm production and oligospermia (low sperm count).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5. Low testosterone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypogonadotropic hypogonadism leads to reduced levels of testosterone because the testes are not adequately stimulated by FSH and LH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The following are not true for hypogonadotropic hypogonadism:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2. High FSH, low LH:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This pattern is more characteristic of hypergonadotropic hypogonadism (primary testicular failure) rather than hypogonadotropic hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4. Low prolactin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypogonadotropic hypogonadism is typically associated with normal or high levels of prolactin if there is an underlying pituitary issue. Low prolactin is not a characteristic feature of hypogonadotropic hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In hypogonadotropic hypogonadism, both FSH and LH levels are low, testosterone levels are low, and oligospermia is often present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 232, DC Dutta&rsquo;s Textbook of Gynecology, 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 24005,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5892,
      "choices": [
        {
          "id": 23538,
          "text": "<p><span style=\"font-size:12pt;\">More than 65 years old</span></p>"
        },
        {
          "id": 23539,
          "text": "<p><span style=\"font-size:12pt;\">Less than 25 years old</span></p>"
        },
        {
          "id": 23540,
          "text": "<p><span style=\"font-size:12pt;\">25 to 65-year-old females</span></p>"
        },
        {
          "id": 23541,
          "text": "<p><span style=\"font-size:12pt;\">Teenagers</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">The following groups of people must be screened for Ca cervix:&nbsp;</span>(INICET NOV 2020)</p>",
      "unique_key": "Q2752467",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769150,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) 25 to 65-year-old females</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">According to the American College of Obstetricians and Gynecologists (ACOG) and the American Cancer Society (ACS) guidelines (2020), cervical cancer screening is recommended for women aged 25 to 65 years. The guidelines specify the following:</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>ACOG/ACS Guidelines (2020):</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12pt;\"><strong>Begin screening at age 25.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Ages 25 to 65:</strong></span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">HPV testing every 5 years (preferred).</span></li><li><span style=\"font-size:12pt;\">HPV/Pap co-testing every 5 years (acceptable).</span></li><li><span style=\"font-size:12pt;\">Pap test alone every 3 years (acceptable).</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Age &gt;65:</strong> No testing required if a series of previous tests were normal.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>WHO Guidelines (2020):</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Begin screening at age 30.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Primary mode of screening:</strong> HPV testing.</span></li><li><span style=\"font-size:12pt;\"><strong>Frequency:</strong> Every 5 to 10 years.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. More than 65 years old:</strong> Screening is generally not required for women over 65 if they have had a series of normal screening results.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Less than 25 years old:</strong> Screening is not recommended for women under 25 according to ACOG/ACS guidelines.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Teenagers:</strong> Screening is not recommended for teenagers as cervical cancer is extremely rare in this age group and the benefits of screening do not outweigh the potential harms.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Cervical cancer screening is recommended for women aged 25 to 65 years, with various acceptable methods and intervals as specified by the ACOG and ACS guidelines.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: ACOG guidelines for screening of cervical cancer, WHO guidelines for screening of cervical cancer, Williams Textbook of gynecology 3<sup>rd</sup> edition 634, 635.</strong></span></p>",
      "correct_choice_id": 23540,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5906,
      "choices": [
        {
          "id": 23594,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LNG- IUCD</span></span></span></p>"
        },
        {
          "id": 23595,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">POP for 3 months</span></span></span></p>"
        },
        {
          "id": 23596,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hysterectomy</span></span></span></p>"
        },
        {
          "id": 23597,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial sampling</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old woman presents with abnormal uterine bleeding for two months. What is the next line of management?&nbsp;</span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q9571089",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769156,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Endometrial sampling</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The next line of management in a 50-year-old woman with abnormal uterine bleeding (AUB) is an endometrial biopsy. This is crucial to rule out endometrial hyperplasia or malignancy, especially in a peri-menopausal woman.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indications for Endometrial Sampling:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peri-menopausal women with AUB.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperestrogenic states like obesity or tamoxifen treatment with thickened endometrium on transvaginal sonography (TVS).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Women with failed medical management and persistent bleeding.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transvaginal ultrasound findings of endometrial thickness &gt;12 mm in premenopausal women and &gt;4 mm in postmenopausal women.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methods of Endometrial Sampling:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Curettage</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration biopsy using Pipelle or Vibra aspirator</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. LNG-IUCD:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The Levonorgestrel intrauterine device (LNG-IUCD) is a treatment option but should be considered after ruling out malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. POP for 3 months:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Progestin-only pills (POP) can be used to manage AUB, but endometrial sampling should be done first to rule out malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hysterectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hysterectomy is a definitive treatment but is considered after other management options and ruling out malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In peri-menopausal women presenting with abnormal uterine bleeding, the first step is to perform endometrial sampling to rule out endometrial hyperplasia or malignancy before considering other treatment modalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Williams Textbook of gynecology 3<sup>rd </sup>edition Pg184</span></strong></span></span></p>",
      "correct_choice_id": 23597,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5952,
      "choices": [
        {
          "id": 23778,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mullerian agenesis</span></span></span></p>"
        },
        {
          "id": 23779,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Gonadal dysgenesis</span></span></span></p>"
        },
        {
          "id": 23780,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Turner syndrome</span></span></span></p>"
        },
        {
          "id": 23781,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Testicular feminization syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 17-year-old girl was brought by her mother to the outpatient department with primary amenorrhea. She had normal breast development and pubic hair. On examination, the vagina was blind-ending and the uterus was not palpable. What is the most probable diagnosis?&nbsp;</span></span>(INICET MAY 2021)</p>",
      "unique_key": "Q9331622",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769348,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Mullerian agenesis</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The given clinical scenario of a girl with primary amenorrhea, normal breasts, and pubic hair, with a blind-ending vagina and uterus not palpable, is suggestive of Mullerian agenesis.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Absent uterus and vagina in a person with female genotype and phenotype are features of Mullerian agenesis, also known as Mayer-Rokitansky-Kuster-Hauser syndrome.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">As ovaries are present, normal secondary sexual characters will develop</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Gonadal dysgenesis</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Gonadal dysgenesis patients present with primary amenorrhoea, absence of secondary sex characters poorly developed breasts</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Turner syndrome</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: In Turner syndrome, short stature with poor development of secondary sexual characters and short stature will be seen. It has a karyotype of 45 XO. The ovaries are streak ovaries</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Testicular feminization syndrome</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Testicular feminization syndrome also known as androgen insensitivity syndrome has a karyotype of 46XY. Secondary sexual characters like the development of axillary hair and pubic hair are absent in these females. However, breast development is adequate due to the conversion of androgen into estrogen during puberty.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mullerian agenesis is characterized by the absence of the uterus and the upper part of the vagina, with normal ovarian function leading to normal breast and pubic hair development.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 450, DC Dutta&rsquo;s Textbook of Gynecology 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23778,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6021,
      "choices": [
        {
          "id": 24054,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Graph A</span></span></span></p>"
        },
        {
          "id": 24055,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Graph B</span></span></span></p>"
        },
        {
          "id": 24056,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Graph C</span></span></span></p>"
        },
        {
          "id": 24057,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Graph D</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following graphs represents normal response to OGTT?&nbsp;</span></span>(INICET MAY 2022)</p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_QetTw5P.jpg\" style=\"height:197px; width:300px\" /></span></span></span></span></p>",
      "unique_key": "Q7698609",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769364,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Graph D</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The normal response to an Oral Glucose Tolerance Test (OGTT) is depicted by Graph D. During an OGTT, a patient ingests a specified amount of glucose (commonly 75 grams), and blood glucose levels are measured at intervals to evaluate how well the body handles glucose. In a normal response:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blood glucose levels rise to a peak within 1 hour after ingestion.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glucose levels then decline and return to baseline by 2 hours.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The glucose levels do not exceed the renal threshold at any point during the test.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This pattern reflects the body&#39;s effective regulation of blood glucose levels and the normal function of insulin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Graph A:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Graph A might depict an abnormal glucose tolerance curve, such as one seen in impaired glucose tolerance or gestational diabetes, where glucose levels remain elevated for a prolonged period or fail to return to baseline.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Graph B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Graph B could show a response with an abnormal peak or delayed return to baseline, indicative of glucose intolerance or a diagnostic criterion for diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Graph C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Graph C might represent an exaggerated glucose peak or prolonged elevated glucose levels, suggesting a pathological glucose tolerance response consistent with diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A normal OGTT response features a peak in blood glucose levels within 1 hour, followed by a return to baseline levels within 2 hours, without exceeding the renal threshold.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><a href=\"https://www.researchgate.net/publication/301045468_VARIANTS_OF_ORAL_GLUCOSE_TOLERANCE_TEST_OGTT_CURVE_IN_GESTATIONAL_DIABETES_MELLITUS_GDM\" style=\"color:#0563c1; text-decoration:underline\"><strong>https://www.researchgate.net/publication/301045468_VARIANTS_OF_ORAL_GLUCOSE_TOLERANCE_TEST_OGTT_CURVE_IN_GESTATIONAL_DIABETES_MELLITUS_GDM</strong></a></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>",
      "correct_choice_id": 24057,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5899,
      "choices": [
        {
          "id": 23566,
          "text": "<p><span style=\"font-size:12pt;\">Abruptio placenta</span></p>"
        },
        {
          "id": 23567,
          "text": "<p><span style=\"font-size:12pt;\">Placenta previa</span></p>"
        },
        {
          "id": 23568,
          "text": "<p><span style=\"font-size:12pt;\">Hydramnios</span></p>"
        },
        {
          "id": 23569,
          "text": "<p><span style=\"font-size:12pt;\">Preterm labour</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">A hypertensive pregnant woman with abdominal pain, bleeding per vaginum, and loss of fetal movements. What is the probable diagnosis?&nbsp;</span>(INICET NOV 2020)</p>",
      "unique_key": "Q7329645",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769154,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Abruptio placenta</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Abruptio placentae, also known as placental abruption, commonly occurs in hypertensive disorders of pregnancy. It is characterized by the premature separation of the placenta from the uterus, leading to painful vaginal bleeding, abdominal pain, and often fetal distress or fetal death. The uterus may be tonically contracted in such cases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Key Points:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Hypertensive Disorders:</strong> Abruptio placentae is frequently associated with hypertensive disorders of pregnancy.</span></li><li><span style=\"font-size:12pt;\"><strong>Clinical Presentation:</strong> Painful vaginal bleeding, abdominal pain, and loss of fetal movements are hallmark signs.</span></li><li><span style=\"font-size:12pt;\"><strong>Uterine Contraction:</strong> The uterus may feel firm and tender, indicating a tonic contraction.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Placenta previa:</strong> Placenta previa involves painless vaginal bleeding due to the placenta covering the cervix. It generally does not cause decreased fetal movements unless there is severe bleeding leading to maternal and fetal compromise.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Hydramnios:</strong> Hydramnios (polyhydramnios) involves excessive amniotic fluid and does not typically present with bleeding.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Preterm labor:</strong> Preterm labor typically does not present with bleeding and is characterized by regular uterine contractions leading to cervical changes before 37 weeks of gestation. Prematurity in preterm labor is iatrogenic if induced.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Abruptio placenta should be suspected in a hypertensive pregnant woman presenting with painful vaginal bleeding, abdominal pain, and loss of fetal movements, as it is commonly associated with hypertensive disorders and presents with these clinical features.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Williams Textbook of obstetrics 26<sup>th</sup> edition pg 1944</strong></span></p>",
      "correct_choice_id": 23566,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5920,
      "choices": [
        {
          "id": 23650,
          "text": "<p><span style=\"font-size:12.0pt;\">3, 4</span></p>"
        },
        {
          "id": 23651,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3</span></p>"
        },
        {
          "id": 23652,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2</span></p>"
        },
        {
          "id": 23653,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following symptoms are seen in endometriosis?&nbsp;</span>(INICET MAY 2021)</p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Infertility</span></li><li><span style=\"font-size:12.0pt;\">Dysmenorrhea</span></li><li><span style=\"font-size:12.0pt;\">Vaginal discharge</span></li><li><span style=\"font-size:12.0pt;\">Vaginal bleeding</span></li></ol>",
      "unique_key": "Q8929105",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769161,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) 1, 2</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Endometriosis is a condition where endometrial tissue, which normally lines the uterus, grows outside the uterus. This condition is associated with specific symptoms:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>1. Infertility</strong>: Women with endometriosis often experience difficulty conceiving. The presence of endometrial tissue outside the uterus can interfere with the reproductive organs, leading to infertility.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>2. Dysmenorrhea</strong>: Painful menstruation is a hallmark of endometriosis. This condition can cause severe menstrual cramps due to the endometrial tissue responding to hormonal changes as it would in a normal menstrual cycle.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. 3, 4</strong>: Vaginal discharge and vaginal bleeding are not characteristic symptoms of endometriosis. Vaginal discharge may be seen in various other conditions but is not specific to endometriosis. Similarly, while endometriosis can cause abnormal bleeding, it typically presents with pain rather than increased vaginal bleeding.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. 2, 3</strong>: While dysmenorrhea (painful menstruation) is a symptom of endometriosis, vaginal discharge is not typically associated with this condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. 2, 4</strong>: Dysmenorrhea is indeed a symptom of endometriosis, but increased vaginal bleeding is not a primary symptom of this condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Endometriosis commonly presents with symptoms including dysmenorrhea (painful menstruation) and infertility.</span></p><p><br><span style=\"font-size:12.0pt;\"><strong>Ref: Page 253, DC Dutta Textbook of Gynecology 8<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23652,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5939,
      "choices": [
        {
          "id": 23726,
          "text": "<p><span style=\"font-size:12.0pt;\">Copper T</span></p>"
        },
        {
          "id": 23727,
          "text": "<p><span style=\"font-size:12.0pt;\">Implanon</span></p>"
        },
        {
          "id": 23728,
          "text": "<p><span style=\"font-size:12.0pt;\">Laparoscopic tubal ligation</span></p>"
        },
        {
          "id": 23729,
          "text": "<p><span style=\"font-size:12.0pt;\">SC DMPA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a long-acting reversible contraceptive method?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q1244543",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769343,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Laparoscopic tubal ligation</strong></span></p><p><br><span style=\"font-size:12.0pt;\"><strong>Laparoscopic tubal ligation</strong> is a permanent form of contraception and is not classified as a long-acting reversible contraceptive (LARC). It involves the surgical closure or blocking of the fallopian tubes to prevent pregnancy permanently.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Long-acting reversible contraceptive (LARC) methods</strong> are effective for extended periods and can be reversed if desired. They include:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Copper T:</strong> Correct. Copper T is an intrauterine device (IUD) that can provide contraception for several years.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Implanon:</strong> Correct. Implanon is a type of contraceptive implant that provides effective contraception for several years.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. SC DMPA:&nbsp;</strong>This is a LARC. It is a sub cutaneous preparation of depot medroxy progesterone acetate and is administered once in 3 months</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Laparoscopic tubal ligation is a permanent method of contraception and is not a long-acting reversible contraceptive (LARC).</span></p>",
      "correct_choice_id": 23728,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5936,
      "choices": [
        {
          "id": 23714,
          "text": "<p><span style=\"font-size:12.0pt;\">Low luteinizing hormone</span></p>"
        },
        {
          "id": 23715,
          "text": "<p><span style=\"font-size:12.0pt;\">High estrogen</span></p>"
        },
        {
          "id": 23716,
          "text": "<p><span style=\"font-size:12.0pt;\">Human somatomammotropin</span></p>"
        },
        {
          "id": 23717,
          "text": "<p><span style=\"font-size:12.0pt;\">Low thyroid-stimulating hormone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Milk production in pregnancy is inhibited by?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q3972758",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769341,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) High estrogen</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Milk production in pregnancy is inhibited primarily by <strong>high estrogen levels</strong>. Although prolactin, an anterior pituitary hormone, is responsible for stimulating milk production (lactogenesis), high levels of estrogen and progesterone during pregnancy prevent the secretion of milk. Estrogen promotes the development of the mammary glands but suppresses milk production. After childbirth, the levels of estrogen and progesterone drop, which allows prolactin to initiate and sustain milk secretion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Low luteinizing hormone:</strong> Incorrect. Luteinizing hormone (LH) is not directly involved in the regulation of milk production. The primary inhibitors are estrogen and progesterone.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Human somatomammotropin:</strong> Incorrect. Human somatomammotropin (also known as human placental lactogen) supports breast development and promotes milk production but does not inhibit it.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Low thyroid-stimulating hormone:</strong> Incorrect. Thyroid-stimulating hormone (TSH) is not a primary factor in inhibiting milk production during pregnancy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">High estrogen levels inhibit milk production during pregnancy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 173, DC Dutta’s Textbook of Obstetrics 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23715,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5956,
      "choices": [
        {
          "id": 23794,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A-1, B-2, C-3, D-4, E-5</span></span></span></p>"
        },
        {
          "id": 23795,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A-1, B-5, C-3, D-2, E-4</span></span></span></p>"
        },
        {
          "id": 23796,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A-1, B-2, C-2, D-3, E-4</span></span></span></p>"
        },
        {
          "id": 23797,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A-2, B-1, C-3, D-4, E-5</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the following:&nbsp;</span></span>(INICET MAY 2021)</p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/26/untitled-233.jpg\" style=\"height:192px; width:400px\" /></p>",
      "unique_key": "Q7126366",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769350,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) A-1, B-5, C-3, D-2, E-4</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/26/untitled-234.jpg\" style=\"height:414px; width:900px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Yolk Sac Tumor is associated with AFP, Choriocarcinoma with Beta hCG, Epithelial Cell Tumor with Ca125, Granulosa Cell Tumor with Inhibin, and Dysgerminoma with LDH.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 521, DC Dutta&rsquo;s Textbook of Gynecology</span></strong></span></span></p>",
      "correct_choice_id": 23795,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6028,
      "choices": [
        {
          "id": 24082,
          "text": "<p><span style=\"font-size:12pt;\">It is best tested in the fasting state on day 2 of menstrual cycle</span></p>"
        },
        {
          "id": 24083,
          "text": "<p><span style=\"font-size:12pt;\">Glycoprotein from granulosa cell of early antral follicle</span></p>"
        },
        {
          "id": 24084,
          "text": "<p><span style=\"font-size:12pt;\">Correlates with pregnancy rate of IVF cycles</span></p>"
        },
        {
          "id": 24085,
          "text": "<p><span style=\"font-size:12pt;\">It decreases sensitivity of the pre-antral follicles to FSH</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">All of the following statements about anti-Mullerian hormones are true, except:&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q1959793",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769367,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) It is best tested in the fasting state on day 2 of menstrual cycle</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Anti-Mullerian Hormone (AMH) is a glycoprotein secreted by the Sertoli cells in males and the granulosa cells of early antral follicles in females. It serves as a marker of ovarian reserve and is crucial in assessing fertility potential. Here are the reasons why option A is incorrect:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>AMH Testing:</strong> Unlike some other hormones, AMH does not require fasting and can be tested at any time during the menstrual cycle. The timing of testing AMH is not restricted to day 2 of the menstrual cycle as with some other reproductive hormone assessments.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Glycoprotein from granulosa cell of early antral follicle</strong>: This is a true statement. AMH is indeed a glycoprotein produced by the granulosa cells of early antral follicles in the ovaries.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Correlates with pregnancy rate of IVF cycles</strong>: This is also true. AMH levels correlate with ovarian reserve and can give an indication of the likelihood of a successful IVF cycle. Higher levels generally suggest a better response to ovarian stimulation and thus potentially higher pregnancy rates.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. It decreases sensitivity of the pre-antral follicles to FSH</strong>: This statement is correct. AMH reduces the sensitivity of pre-antral and small antral follicles to Follicle-Stimulating Hormone (FSH), which is a mechanism to regulate follicle recruitment and maturation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Anti-Mullerian Hormone (AMH) does not need to be tested in the fasting state or specifically on day 2 of the menstrual cycle.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 76, DC Dutta’s Textbook of Gynecology 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 24082,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6000,
      "choices": [
        {
          "id": 23970,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inj. Dobutamine</span></span></span></p>"
        },
        {
          "id": 23971,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroids</span></span></span></p>"
        },
        {
          "id": 23972,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroxine</span></span></span></p>"
        },
        {
          "id": 23973,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activated protein C</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old lady had an uneventful vaginal delivery. On postpartum day 1, she presented with postpartum hemorrhage and complains of visual changes and severe headache. A few hours after the complaint, she is found to be in an unresponsive state and is intubated and put on ventilation. On further examination, she has a BP of 60/40 mmHg and tachycardia, blood sugar is 48 mg/dL. Hematocrit and WBC count was normal. Which of the following drugs would help reverse this state?&nbsp;</span></span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q3037125",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769352,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Steroids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The clinical presentation described&mdash;postpartum hemorrhage followed by severe headache, visual changes, hypotension, and unresponsiveness&mdash;suggests Sheehan syndrome. This condition arises from pituitary apoplexy, which is pituitary infarction secondary to severe blood loss during or after childbirth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sheehan Syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This syndrome is characterized by pituitary gland failure due to substantial blood loss during delivery. The symptoms include persistent hypotension, tachycardia, hypoglycemia, lactation failure, headache, visual deficits, and in severe cases, shock, CNS hemorrhage, and even death.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroids</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Hormone replacement with glucocorticoids (steroids) is crucial for managing Sheehan syndrome. Steroids address the adrenal insufficiency and help stabilize the patient&rsquo;s condition. Initially, glucocorticoids are administered, followed by other hormone replacements as needed.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Inj. Dobutamine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Dobutamine is a beta-agonist used for managing cardiac failure and hypotension. While it may help with blood pressure, it does not address the underlying issue of pituitary failure and would not be the primary treatment for Sheehan syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Thyroxine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Thyroxine (T4) is a thyroid hormone used in thyroid hormone replacement therapy. While it might be needed later if thyroid function is affected, it does not directly address the acute symptoms of Sheehan syndrome, which is primarily managed with steroids.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Activated Protein C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Activated protein C is used in the management of severe sepsis and disseminated intravascular coagulation (DIC), but it does not treat the pituitary dysfunction associated with Sheehan syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sheehan syndrome is treated primarily with glucocorticoid (steroid) therapy to manage pituitary failure following significant blood loss during or after childbirth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 378, Williams Gynecology 3<sup>rd</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23971,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5935,
      "choices": [
        {
          "id": 23710,
          "text": "<p><span style=\"font-size:12.0pt;\">50 mcg</span></p>"
        },
        {
          "id": 23711,
          "text": "<p><span style=\"font-size:12.0pt;\">150 mcg</span></p>"
        },
        {
          "id": 23712,
          "text": "<p><span style=\"font-size:12.0pt;\">200 mcg</span></p>"
        },
        {
          "id": 23713,
          "text": "<p><span style=\"font-size:12.0pt;\">100 mcg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the dose of carbetocin used in the prevention of postpartum hemorrhage?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q9789325",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769340,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) 100 mcg</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">100 mcg of carbetocin is used in the <strong>prevention</strong> of postpartum hemorrhage (PPH).</span></li><li><span style=\"font-size:12.0pt;\">The use of carbetocin (100 mcg, IM/IV) is recommended for the prevention of PPH.</span></li><li><span style=\"font-size:12.0pt;\">It is a long-acting synthetic analog of oxytocin which is stable at room temperature (unlike oxytocin which needs the cold chain to be maintained.</span></li><li><span style=\"font-size:12.0pt;\">To effectively prevent PPH, the WHO recommends the use of only one of the following uterotonic agents:</span><ul><li><span style=\"font-size:12.0pt;\">Oxytocin (10 IU - IM/IV)</span></li><li><span style=\"font-size:12.0pt;\">Carbetocin (100 ug - IM/IV)</span></li><li><span style=\"font-size:12.0pt;\">Misoprostol (400 g or 600 g, per-oral)</span></li><li><span style=\"font-size:12.0pt;\">Ergometrine/methylergometrine (200 ug - IM/IV)</span></li><li><span style=\"font-size:12.0pt;\">Oxytocin and ergometrine fixed-dose combination (5 IU,500g - IM)</span></li></ul></li><li><span style=\"font-size:12.0pt;\">Of these, oxytocin is used as the first-line agent (drug of choice) for AMTSL.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">The recommended dose of carbetocin for the prevention of postpartum hemorrhage is 100 mcg, administered either IM or IV.</span></p>",
      "correct_choice_id": 23713,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6019,
      "choices": [
        {
          "id": 24046,
          "text": "<p><span style=\"font-size:12pt;\">Cystic fibrosis</span></p>"
        },
        {
          "id": 24047,
          "text": "<p><span style=\"font-size:12pt;\">Klinefelter syndrome</span></p>"
        },
        {
          "id": 24048,
          "text": "<p><span style=\"font-size:12pt;\">Kallmann syndrome</span></p>"
        },
        {
          "id": 24049,
          "text": "<p><span style=\"font-size:12pt;\">Kartagener syndrome</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Seminal vesicles and vas deferens would be bilaterally absent congenitally in which of the following conditions?&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q7212525",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769363,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Cystic fibrosis</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Seminal vesicles and vas deferens would be bilaterally absent, congenitally in cystic fibrosis. This is known as the congenital bilateral absence of vas deference (CBAVD) and is a causes of obstructive azoospermia</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Klinefelter syndrome</strong>: Klinefelter syndrome (47 XXY) accounts or 1 to 2 percent of male infertility cases. Classically, these men are tall, undervirilized, and have gynecomastia and small, rm testes</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Kallman syndrome</strong>: This is a form of congenital hypogonadotrophic hypogonadism with anosmia. It presents as primary amenorrhoea in women and with male infertility in men</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Kartagener syndrome</strong>: Kartagener's syndrome is a rare, autosomal recessive genetic ciliary disorder comprising the triad of situs inversus, chronic sinusitis, and bronchiectasis. The basic problem lies in the defective movement of cilia, leading to recurrent chest infections, ear/nose/throat symptoms, and infertility.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Cystic fibrosis is associated with congenital bilateral absence of the seminal vesicles and vas deferens, leading to obstructive azoospermia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 229, DC Dutta’s Textbook of Gynecology 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 24046,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5914,
      "choices": [
        {
          "id": 23626,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Albumin</span></span></span></p>"
        },
        {
          "id": 23627,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platelet</span></span></span></p>"
        },
        {
          "id": 23628,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibrinogen</span></span></span></p>"
        },
        {
          "id": 23629,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-thrombin antibody</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raise in ESR during pregnancy is due to?&nbsp;</span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q2263564",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769160,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Fibrinogen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pregnancy is characterized as a hypercoagulable state, and several changes occur in the coagulation system during pregnancy. One of the significant changes is the increase in fibrinogen levels, which leads to a rise in the erythrocyte sedimentation rate (ESR).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key Points:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibrinogen Levels:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> During pregnancy, fibrinogen levels increase by approximately 50%, from 200-400 mg/dL to 300-600 mg/dL. This rise in fibrinogen contributes significantly to the increased ESR.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ESR:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The ESR can increase up to four times during pregnancy due to the increased levels of fibrinogen and globulin.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platelet Count:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> There may be a slight fall in platelet count during pregnancy, commonly due to gestational thrombocytopenia, which is caused by hemodilution and increased platelet consumption. This condition usually has no adverse effect on pregnancy and is often observed in the third trimester.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Coagulation Factors:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> There is an increase in the plasma levels of several coagulation factors, including factors 1 (fibrinogen), 2, 7, 8, 9, and 10. Factors 2, 5, and 12 remain unchanged or mildly increased, while factors 11 and 13 are slightly decreased.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clotting Time:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clotting time is generally unaffected by pregnancy.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-Thrombin III:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Levels of anti-thrombin III decrease during pregnancy.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Albumin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Albumin levels typically decrease during pregnancy due to hemodilution, and they do not contribute to the rise in ESR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Platelet:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Platelet count may slightly decrease due to gestational thrombocytopenia, but this does not contribute to the rise in ESR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Anti-thrombin antibody:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is not a relevant factor in the context of ESR increase during pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The rise in erythrocyte sedimentation rate (ESR) during pregnancy is primarily due to the increased levels of fibrinogen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition Pg59</span></strong></span></span></p>",
      "correct_choice_id": 23628,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5950,
      "choices": [
        {
          "id": 23770,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3</span></p>"
        },
        {
          "id": 23771,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3, 4</span></p>"
        },
        {
          "id": 23772,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 4</span></p>"
        },
        {
          "id": 23773,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A teenage girl presented with irregular cycles and increased facial hair. Her ovaries showed increased volume. Which of the following are used in the first line treatment?&nbsp;</span>(INICET MAY 2021)</p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Laparoscopic ovarian drilling</span></li><li><span style=\"font-size:12.0pt;\">Anti-androgens</span></li><li><span style=\"font-size:12.0pt;\">Lifestyle modifications</span></li><li><span style=\"font-size:12.0pt;\">Combined oral contraceptive pills</span></li></ol>",
      "unique_key": "Q1176513",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769346,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) 2, 3, 4</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">The clinical presentation of irregular menstrual cycles and increased facial hair, combined with increased ovarian volume, is suggestive of <strong>polycystic ovarian syndrome (PCOS)</strong>. The first-line treatment options for PCOS typically include:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Anti-androgens</strong> (2): These medications help reduce symptoms related to excess androgens, such as facial hair and acne. Common examples include spironolactone.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Lifestyle modifications</strong> (3): These are crucial for managing PCOS. Weight loss and exercise can improve insulin sensitivity and help regulate menstrual cycles.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Combined oral contraceptive pills</strong> (4): These are used to regulate menstrual cycles, reduce hyperandrogenism symptoms (like hirsutism), and provide endometrial protection.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Laparoscopic ovarian drilling</strong> (1): This is a surgical procedure used to treat PCOS, but it is generally considered a second-line treatment. It is typically performed when medical management fails to achieve the desired results.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">The first-line treatments for PCOS include anti-androgens, lifestyle modifications, and combined oral contraceptive pills.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 460, DC Dutta’s Textbook of Gynecology 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23771,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5909,
      "choices": [
        {
          "id": 23606,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hysterectomy</span></span></span></p>"
        },
        {
          "id": 23607,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myomectomy</span></span></span></p>"
        },
        {
          "id": 23608,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No intervention as the patient is asymptomatic</span></span></span></p>"
        },
        {
          "id": 23609,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medical management</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman is found to have a fibroid of 14 weeks size. She has no specific symptoms. What is the next step in management?&nbsp;</span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q8734014",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769158,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) No intervention as the patient is asymptomatic</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the case of an asymptomatic fibroid, intervention is generally not required regardless of the size. The management approach is typically conservative, involving observation and regular monitoring.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key Points:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asymptomatic Fibroids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fibroids that do not cause symptoms do not require immediate intervention. Instead, they can be observed with yearly ultrasounds or reviewed earlier if symptoms develop.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Common Symptoms of Fibroids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These include heavy menstrual bleeding, dysmenorrhea, pressure symptoms, and the presence of an abdominal mass.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Management of Symptomatic Fibroids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Depending on the patient&#39;s age, size of the fibroid, number, and location, symptomatic fibroids may be considered for myomectomy or hysterectomy.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hysterectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a major surgical procedure and is typically reserved for symptomatic fibroids or when other treatment options have failed or are not suitable.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Myomectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Myomectomy is a surgical procedure to remove fibroids and is considered for symptomatic patients who wish to preserve their uterus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Medical management:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Medical management is used to manage symptoms and is not necessary for asymptomatic fibroids.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In asymptomatic patients with fibroids, intervention is generally not required. Observation and regular monitoring are appropriate unless symptoms develop, in which case, further management options such as myomectomy or hysterectomy may be considered.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Williams Textbook of gynecology 3<sup>rd</sup>edition Pg207</span></strong></span></span></p>",
      "correct_choice_id": 23608,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5820,
      "choices": [
        {
          "id": 23250,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morphology</span></span></span></p>"
        },
        {
          "id": 23251,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Concentration</span></span></span></p>"
        },
        {
          "id": 23252,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Motility</span></span></span></p>"
        },
        {
          "id": 23253,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sperm Count</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most important marker of male fertility in semen analysis is?&nbsp;</span></span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q8780474",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769133,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Morphology</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The morphology of sperm is considered the most important marker of male fertility. While sperm concentration and progressive motility are valuable for distinguishing between fertile and infertile men, strict sperm morphology is the most discriminating factor in assessing male fertility potential.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morphological abnormalities in spermatozoa can be identified in various parts, including the head, neck, mid-piece, and tail. These abnormalities can result from defective spermatogenesis or certain epididymal pathologies, leading to increased morphological defects in the sperm. Spermatozoa with abnormal morphology have a lower fertilizing potential, making morphology a critical parameter in semen analysis for determining fertility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Concentration:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sperm concentration is an important parameter, but it is not as critical as morphology in predicting fertility. The WHO 2021 standard for sperm concentration is 16 million/ml.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Motility:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Progressive motility is significant, with the WHO 2021 standard being 30%, but it is not the most crucial parameter compared to morphology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Sperm Count:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While total sperm count is important, it is encompassed under concentration and motility measures. Morphology remains the most critical individual parameter.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sperm morphology is the most important marker of male fertility in semen analysis, as it directly correlates with the fertilizing potential of the sperm.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/02/untitled-288.jpg\" style=\"height:351px; width:900px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of gynecology 3<sup>rd</sup> edition pg443, </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><a href=\"https://www.who.int/publications/i/item/9789240030787\" style=\"color:blue; text-decoration:underline\"><strong>https://www.who.int/publications/i/item/9789240030787</strong></a></span></span></span></p>",
      "correct_choice_id": 23250,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5875,
      "choices": [
        {
          "id": 23470,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hot flashes</span></span></span></p>"
        },
        {
          "id": 23471,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CAD Prophylaxis</span></span></span></p>"
        },
        {
          "id": 23472,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteoporosis</span></span></span></p>"
        },
        {
          "id": 23473,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Premature menopause</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormone Replacement Therapy is not indicated for:&nbsp;</span></span></span>(INICET NOV 2019)</p>",
      "unique_key": "Q3545924",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769147,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) CAD Prophylaxis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormone Replacement Therapy (HRT) is not recommended for the prophylaxis of coronary artery disease (CAD). Although there was some belief in the past that HRT might provide cardiovascular benefits, extensive research has shown that HRT does not prevent CAD and may, in fact, increase the risk of certain cardiovascular events in some women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRT is primarily indicated for the management of symptoms associated with menopause and for certain therapeutic and prophylactic uses:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therapeutic Indications:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadal dysgenesis in adolescents</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Premature ovarian failure</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hot flashes (vasomotor symptoms)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vaginal dryness</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prophylactic Indications:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prevention of osteoporosis in postmenopausal women</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risks of HRT:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of endometrial cancer (particularly with unopposed estrogen in women with an intact uterus)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of breast cancer</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of ovarian cancer</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of thromboembolism</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Possible adverse effects on lipid profiles</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of gallstones and liver dysfunction</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hot flashes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> HRT is widely used to manage hot flashes and other vasomotor symptoms associated with menopause. It is one of the most effective treatments for these symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Osteoporosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> HRT is used prophylactically to prevent osteoporosis in postmenopausal women by maintaining bone density and reducing the risk of fractures.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Premature menopause:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Women experiencing premature menopause or premature ovarian failure can benefit from HRT to manage symptoms and reduce the long-term risks associated with early loss of estrogen, including osteoporosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormone Replacement Therapy (HRT) is not indicated for the prophylaxis of coronary artery disease (CAD).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of gynecology 6<sup>th</sup> edition pg 61,62</span></strong></span></span></p>",
      "correct_choice_id": 23471,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5949,
      "choices": [
        {
          "id": 23766,
          "text": "<p><span style=\"font-size:12.0pt;\">Oligomenorrhea</span></p>"
        },
        {
          "id": 23767,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypomenorrhea</span></p>"
        },
        {
          "id": 23768,
          "text": "<p><span style=\"font-size:12.0pt;\">Dysmenorrhea</span></p>"
        },
        {
          "id": 23769,
          "text": "<p><span style=\"font-size:12.0pt;\">Menorrhagia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Asherman syndrome is most commonly associated with?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q8163052",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769345,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Hypomenorrhea</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Asherman syndrome is the presence of uterine synechiae, due to the destruction of the endometrium. It can occur because of</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12.0pt;\">Trauma to the endometrium following vigorous curettages such as incomplete abortion, postpartum hemorrhage, and elective abortion.</span></li><li><span style=\"font-size:12.0pt;\">Genital tuberculosis</span></li></ul></li><li><span style=\"font-size:12.0pt;\">C/F: Following a D &amp; C, they present with</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12.0pt;\">Hypomenorrhea</span></li><li><span style=\"font-size:12.0pt;\">Secondary amenorrhoea</span></li><li><span style=\"font-size:12.0pt;\">Secondary infertility</span></li></ul></li><li><span style=\"font-size:12.0pt;\">The diagnosis is made by</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12.0pt;\">HSG: Moth eaten appearance/ intra cavitary filling defects</span></li><li><span style=\"font-size:12.0pt;\">Hysteroscopy: Intra uterine adhesions are seen</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/05/screenshot-2024-08-05-171526.png\" alt=\"\" width=\"500\" height=\"234\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Management: Hysteroscopic adhesiolysis f/b insertion of an IUCD for 3 months and giving estrogen to build the endometrium</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>&nbsp;Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Oligomenorrhea</strong>: This refers to infrequent menstruation, which is not the primary symptom of Asherman syndrome. Although it can occur, hypomenorrhea is more characteristic of the condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Dysmenorrhea</strong>: This means painful menstruation, which is not typically associated with Asherman syndrome.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Menorrhagia</strong>: This refers to heavy menstrual bleeding. Asherman syndrome usually leads to hypomenorrhea rather than menorrhagia due to the reduced endometrial surface area.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Asherman syndrome is most commonly associated with hypomenorrhea due to intrauterine adhesions following endometrial trauma.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 459, DC Dutta’s Textbook of gynecology 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23767,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5921,
      "choices": [
        {
          "id": 23654,
          "text": "<p><span style=\"font-size:12.0pt;\">Metronidazole</span></p>"
        },
        {
          "id": 23655,
          "text": "<p><span style=\"font-size:12.0pt;\">Fluconazole</span></p>"
        },
        {
          "id": 23656,
          "text": "<p><span style=\"font-size:12.0pt;\">Tetracycline</span></p>"
        },
        {
          "id": 23657,
          "text": "<p><span style=\"font-size:12.0pt;\">Cefixime</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A female patient having frothy vaginal discharge was found to have a strawberry cervix. Which of the following is the drug of choice?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q5912024",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769162,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Metronidazole</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">The description of a frothy vaginal discharge and a \"strawberry cervix\" is characteristic of <strong>trichomoniasis vaginalis</strong>, a common sexually transmitted infection caused by the protozoan Trichomonas vaginalis. The drug of choice for treating trichomoniasis is <strong>Metronidazole</strong>. This medication can be administered as a single high dose (2g) or in a lower dose (200mg three times daily for 7 days).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Fluconazole</strong>: This drug is used for treating candidiasis (yeast infections), not trichomoniasis. Candidiasis typically presents with a curdy white discharge rather than frothy discharge and is not associated with a strawberry cervix.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Tetracycline</strong>: Tetracycline is an antibiotic used for various bacterial infections but is not effective against trichomoniasis. It is not the drug of choice for treating this parasitic infection.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Cefixime</strong>: Cefixime is a cephalosporin antibiotic used to treat bacterial infections like gonorrhea. It is not effective against trichomoniasis and thus is not appropriate for this condition.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/05/screenshot-2024-08-05-164120.png\" alt=\"\" width=\"1000\" height=\"434\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">The drug of choice for treating trichomoniasis vaginalis, which presents with frothy vaginal discharge and strawberry cervix, is Metronidazole.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 554, DC Dutta’s Textbook of gynecology 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23654,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5823,
      "choices": [
        {
          "id": 23262,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supine with wedge under right hip</span></span></span></p>"
        },
        {
          "id": 23263,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Semi fowlers</span></span></span></p>"
        },
        {
          "id": 23264,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trendelenburg with legs stirrup</span></span></span></p>"
        },
        {
          "id": 23265,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prone position</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A woman presents with prolonged labor in emergency. She is being taken for a Cesarean section. Which of the following is the correct position in which the nurse should keep the patient on the OT table?&nbsp;</span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q6047962",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769136,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Supine with wedge under right hip</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The preferred position for a cesarean section is supine with a wedge under the right hip. This positioning is crucial to prevent supine hypotension syndrome, which is commonly seen in the third trimester of pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supine hypotension syndrome:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Occurs due to the pressure of the gravid uterus on the inferior vena cava (IVC) when the patient is in the supine position.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This pressure can cause hypotension, tachycardia, and syncope.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is particularly dangerous during cesarean sections where spinal anesthesia can exacerbate hypotension.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A right tilt (placing a wedge under the right hip) helps to alleviate the pressure on the IVC, thereby preventing hypotension.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Semi fowlers:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The individual lies on the bed with the head elevated 30-45 degrees. This position is not suitable for a cesarean section.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Trendelenburg with legs stirrup:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This position involves having the head low and is not appropriate for a cesarean section. The reverse Trendelenburg position (head high) is also not suitable for this purpose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Prone position:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The prone position (lying face down) is inappropriate for cesarean sections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a cesarean section, the patient should be positioned supine with a wedge under the right hip to prevent supine hypotension syndrome, which is caused by the pressure of the gravid uterus on the inferior vena cava.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition pg 1405</span></strong></span></span></p>",
      "correct_choice_id": 23262,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5923,
      "choices": [
        {
          "id": 23662,
          "text": "<p><span style=\"font-size:12.0pt;\">&gt;92 mg/dL</span></p>"
        },
        {
          "id": 23663,
          "text": "<p><span style=\"font-size:12.0pt;\">&gt;95 mg/dL</span></p>"
        },
        {
          "id": 23664,
          "text": "<p><span style=\"font-size:12.0pt;\">&gt;106 mg/dL</span></p>"
        },
        {
          "id": 23665,
          "text": "<p><span style=\"font-size:12.0pt;\">&gt;90 mg/dL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">According to IADPSG, what is the cut-off value of fasting blood glucose for the diagnosis of gestational diabetes mellitus?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q2873248",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769163,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) &gt; 92 mg/dL</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The International Association of Diabetes and Pregnancy Study Groups (IADPSG) has established criteria for the diagnosis of gestational diabetes mellitus (GDM). According to their guidelines:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The fasting blood glucose cut-off value for diagnosing GDM during a 75g oral glucose tolerance test (OGTT) is <strong>&gt;92 mg/dL</strong>.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This value is used as part of a comprehensive assessment, including 1-hour and 2-hour postprandial glucose levels. The IADPSG criteria for GDM diagnosis include:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Fasting:</strong> ≥92 mg/dL</span></li><li><span style=\"font-size:12.0pt;\"><strong>1-hour:</strong> ≥180 mg/dL</span></li><li><span style=\"font-size:12.0pt;\"><strong>2-hour:</strong> ≥153 mg/dL</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">If any one of these values is abnormal, the diagnosis of GDM can be made.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. &gt;95 mg/dL</strong>: This is not the IADPSG recommended cut-off for fasting blood glucose. It is higher than the specified cut-off value for diagnosing GDM.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. &gt;106 mg/dL</strong>: This value is significantly higher than the recommended cut-off. It exceeds the threshold for diagnosing GDM according to IADPSG guidelines.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. &gt;90 mg/dL</strong>: While this value is close, it is slightly below the IADPSG recommended cut-off of &gt;92 mg/dL for diagnosing GDM.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The cut-off value of fasting blood glucose for the diagnosis of gestational diabetes mellitus according to IADPSG is &gt;92 mg/dL.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 326, DC Dutta’s Textbook of Obstetrics 8<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23662,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5951,
      "choices": [
        {
          "id": 23774,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cusco&#39;s speculum</span></span></span></p>"
        },
        {
          "id": 23775,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">﻿﻿﻿Sims&#39; speculum</span></span></span></p>"
        },
        {
          "id": 23776,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">﻿﻿﻿Proctoscope</span></span></span></p>"
        },
        {
          "id": 23777,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">﻿﻿﻿Doyen&#39;s retractor</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the instrument given below?&nbsp;</span></span>(INICET MAY 2021)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_FFzm3FJ.jpg\" style=\"height:210px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q5342223",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769347,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Cusco&#39;s speculum</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The instrument shown in the image is Cusco&#39;s speculum.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cusco&#39;s speculum is a self-retaining bivalve speculum used for visualization of the cervix, vaginal fornices and for performing pap smear.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Advantage: Self retaining</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Disadvantage: Less space so can&rsquo;t be used for some procedures, obscures the vaginal walls so vaginal lesion may be missed</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Sim Speculum:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/26/untitled-230.jpg\" style=\"height:250px; width:250px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Proctoscope</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/26/untitled-231.jpg\" style=\"height:250px; width:250px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Doyen Retractor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/26/untitled-232.jpg\" style=\"height:410px; width:250px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cusco&#39;s speculum is a self-retaining bivalve speculum used for visualizing the cervix and vaginal fornices.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 628, DC Dutta&rsquo;s Textbook of Gynecology 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23774,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET",
        "InstrumentsBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5928,
      "choices": [
        {
          "id": 23682,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mandatory episiotomy</span></span></span></p>"
        },
        {
          "id": 23683,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Manual perineal support and warm compresses</span></span></span></p>"
        },
        {
          "id": 23684,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Maintain head in deflexion and deliver</span></span></span></p>"
        },
        {
          "id": 23685,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Deliver in lithotomy position only</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is recommended by the WHO for the management of the second stage of labor?&nbsp;</span></span>(INICET MAY 2021)</p>",
      "unique_key": "Q5516794",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769166,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Manual perineal support and warm compresses</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The WHO guidelines for managing the second stage of labor emphasize techniques to reduce perineal trauma and enhance maternal comfort. The use of manual perineal support and warm compresses is recommended to protect the perineum during delivery and reduce the incidence of severe perineal tears.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Manual Perineal Support and Warm Compresses:</span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Manual Support:</span></strong><span style=\"font-size:12.0pt\"> Hands-on guarding of the perineum during delivery helps control the speed of delivery and reduces the risk of severe perineal tears.</span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Warm Compresses:</span></strong><span style=\"font-size:12.0pt\"> Applying warm compresses to the perineum can help relax the tissues and make them more pliable, further reducing the risk of tearing.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mandatory Episiotomy:&nbsp;</span></strong></span></span><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Not Recommended:</span></strong><span style=\"font-size:12.0pt\"> Routine episiotomy is no longer recommended by the WHO. It is only indicated in specific cases where it is necessary to expedite delivery for the safety of the mother or baby.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Maintain Head in Deflexion and Deliver:&nbsp;</span></strong></span></span><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Not Recommended:</span></strong><span style=\"font-size:12.0pt\"> The recommendation is to allow the fetal head to assume the most optimal position for delivery rather than intentionally maintaining deflexion, which may hinder the delivery process.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Deliver in Lithotomy Position Only:&nbsp;</span></strong></span></span><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Not Recommended:</span></strong><span style=\"font-size:12.0pt\"> The WHO supports a variety of birthing positions based on the mother&rsquo;s preference and comfort. Restricting delivery to the lithotomy position is not recommended; instead, women should be encouraged to choose their preferred position.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Manual perineal support and warm compresses are recommended by the WHO to reduce perineal trauma during the second stage of labor.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref:&nbsp;</span></strong><a href=\"https://iris.who.int/bitstream/handle/10665/337693/9789240017566-eng.pdf\" style=\"color:#0563c1; text-decoration:underline\"><strong><span style=\"font-size:12.0pt\">https://iris.who.int/bitstream/handle/10665/337693/9789240017566-eng.pdf</span></strong></a></span></span></p>",
      "correct_choice_id": 23683,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6017,
      "choices": [
        {
          "id": 24038,
          "text": "<p><span style=\"font-size:12pt;\">Growth of 10<sup>3</sup> coliform in suprapubic sample</span></p>"
        },
        {
          "id": 24039,
          "text": "<p><span style=\"font-size:12pt;\">Growth of 10<sup>5</sup> coliform in voided urine sample</span></p>"
        },
        {
          "id": 24040,
          "text": "<p><span style=\"font-size:12pt;\">Frequency with dysuria with &gt;3 WBC/HPF</span></p>"
        },
        {
          "id": 24041,
          "text": "<p><span style=\"font-size:12pt;\">Frequency with dysuria with positive nitrite and leucoesterase dipstick test</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Urinary tract infection in a pregnant lady in her 2nd trimester is best defined as:&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q6065375",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769361,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Growth of 10<sup>5</sup> coliform in voided urine sample</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">A urinary tract infection (UTI) in a pregnant woman is best defined by the growth of 10^5 coliforms per milliliter in a voided urine sample. This threshold is used to differentiate significant bacterial growth from contamination or a non-infectious presence of bacteria.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In pregnancy, the standard diagnostic method for UTI is a urine culture. A growth of 10^5 or more coliforms per milliliter in a properly collected voided urine sample is considered diagnostic for UTI.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Growth of 103 coliform in suprapubic sample:</strong> Growth of 10^3 coliforms in a suprapubic sample is <strong>not a standard criterion</strong> for diagnosing UTI. Typically, suprapubic aspiration is used for more precise diagnoses, and lower thresholds may be acceptable due to reduced contamination risk compared to voided samples. However, for voided samples, the threshold is higher.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Frequency with dysuria with &gt;3 WBC/HPF:</strong> Frequency with dysuria and &gt;3 WBC/HPF indicates inflammation and <strong>possible infection</strong> but does not define a UTI by itself. The presence of WBCs in urine is a sign of inflammation or infection but is not specific for diagnosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Frequency with dysuria with positive nitrite and leucoesterase dipstick test:</strong> Frequency with dysuria and positive nitrite and leucocyte esterase dipstick tests <strong>suggest a UTI but are not definitive</strong>. These tests are helpful as preliminary screening tools but are not as definitive as a quantitative urine culture.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">A urinary tract infection in a pregnant lady in her 2nd trimester is best defined as the growth of 10^5 coliforms in a voided urine sample.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 348, DC Dutta’s Textbook of Obstetrics 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 24039,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5841,
      "choices": [
        {
          "id": 23334,
          "text": "<p><span style=\"font-size:12pt;\">3 mm</span></p>"
        },
        {
          "id": 23335,
          "text": "<p><span style=\"font-size:12pt;\">4 mm</span></p>"
        },
        {
          "id": 23336,
          "text": "<p><span style=\"font-size:12pt;\">7 mm</span></p>"
        },
        {
          "id": 23337,
          "text": "<p><span style=\"font-size:12pt;\">9 mm</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the minimum endometrial thickness on transvaginal ultrasonography, above which you perform a biopsy in a case of postmenopausal bleeding?&nbsp;</span>(INICET NOV 2018)</p>",
      "unique_key": "Q6699392",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769140,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) 4 mm</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Post menopausal bleeding with a finding of endometrial thickness greater than 4 mm (5 mm or more) requires further evaluation, i.e., a biopsy of the endometrium.</span></li><li><span style=\"font-size:12pt;\">If the endometrial thickness is ≤4 mm, then malignancy is unlikely and the likely cause of bleeding being endometrial atrophy and there is no need of a biopsy.</span></li><li><span style=\"font-size:12pt;\">The most common cause of post-menopausal bleeding is atrophic endometritis</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In postmenopausal women with bleeding, an endometrial thickness greater than 4 mm on transvaginal ultrasonography should prompt further evaluation with an endometrial biopsy to rule out malignancy or other significant pathology.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: William’s textbook of gynecology 3<sup>rd</sup> edition pg 186, Dutta’s textbook of gynecology 6<sup>th</sup> edition pg 357</strong></span></p>",
      "correct_choice_id": 23335,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "CriteriaBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5864,
      "choices": [
        {
          "id": 23426,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conization</span></span></span></p>"
        },
        {
          "id": 23427,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cryotherapy</span></span></span></p>"
        },
        {
          "id": 23428,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Targeted biopsy</span></span></span></p>"
        },
        {
          "id": 23429,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pap smear</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman comes with a history of postcoital bleeding and a visible mass seen in cervix per speculum. The next step to be done? (AIIMS NOV 2019)</span></span></p>",
      "unique_key": "Q1017402",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769141,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Targeted biopsy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A targeted biopsy (punch biopsy) is the next line of management in the above case as the patient is symptomatic (postcoital bleeding) and has a visible lesion. The biopsy will help in diagnosing the nature of the lesion, which is crucial for further management.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Conization:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Conization is an excisional procedure done once biopsy-proven intraepithelial neoplasia (CIN 2 and 3) is diagnosed. It is not the initial step when a visible lesion is present and needs to be assessed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Cryotherapy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Cryotherapy is an ablative procedure done for CIN 1 or 2. It is not suitable for a visible lesion with postcoital bleeding without a prior biopsy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pap smear:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Pap smear is done when there are symptoms with no identifiable lesion. In the presence of a visible mass, a direct biopsy is more appropriate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a symptomatic patient with postcoital bleeding and a visible lesion on the cervix, the next step is a targeted biopsy to diagnose the nature of the lesion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of gynecology 3<sup>rd</sup> edition pg662, Dutta&rsquo;s textbook of gynecology 6<sup>th</sup> edition pg345</span></strong></span></span></p>",
      "correct_choice_id": 23428,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5839,
      "choices": [
        {
          "id": 23326,
          "text": "<p><span style=\"font-size:12pt;\">USG to see cervical length</span></p>"
        },
        {
          "id": 23327,
          "text": "<p><span style=\"font-size:12pt;\">Cervical Cerclage</span></p>"
        },
        {
          "id": 23328,
          "text": "<p><span style=\"font-size:12pt;\">Complete Bed rest</span></p>"
        },
        {
          "id": 23329,
          "text": "<p><span style=\"font-size:12pt;\">Abdominal cerclage</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A G3P2L0 presents with 9 weeks of amenorrhea. She has a history of conization being done one year ago and is currently on follow-up, with no recurrence on PAP smear. She also has the history of preterm labor at 30 and 32 weeks. What is the next step of management?&nbsp;</span>(INICET NOV 2018)</p>",
      "unique_key": "Q1377356",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769139,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) USG to see cervical length</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">This patient has several risk factors for preterm labor, including a history of previous preterm births and cervical conization. The appropriate next step in management is to perform a transvaginal ultrasound (USG) to measure the cervical length at 11-14 weeks of gestation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Key Points:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Cervical length measurement:</strong> If the cervix is found to be short (less than 2.5 cm), with or without funneling of the internal os, cervical cerclage may be indicated.</span></li><li><span style=\"font-size:12pt;\"><strong>Progesterone supplementation:</strong> If the cervical length is normal, the patient should be started on progesterone and serial cervical length measurements should be continued.</span></li><li><span style=\"font-size:12pt;\"><strong>Cervical cerclage:</strong> This is a procedure where a suture is placed around the cervix to prevent or delay preterm birth. It can be done via the vaginal route using techniques like McDonald’s or Shirodkar's.</span></li><li><span style=\"font-size:12pt;\"><strong>Abdominal cerclage:</strong> This is considered for patients with a prior failed vaginal cerclage.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Cervical Cerclage:</strong> While cerclage may be necessary, it should be based on the findings of cervical length measurement. Immediate cerclage without assessment is not recommended.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Complete Bed rest:</strong> Bed rest alone is not an effective strategy for preventing preterm labor and is not indicated without further assessment.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Abdominal cerclage:</strong> This is reserved for patients with a history of failed vaginal cerclage and is not the first-line approach.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">For a patient with risk factors for preterm labor, including a history of cervical conization and previous preterm births, the next step is to perform a transvaginal ultrasound to measure cervical length at 11-14 weeks of gestation. Based on the findings, appropriate interventions, such as cervical cerclage or progesterone supplementation, can be considered.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: William’s textbook of obstetrics 26<sup>th</sup> edition pg2094</strong></span></p>",
      "correct_choice_id": 23326,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5898,
      "choices": [
        {
          "id": 23562,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Declare as complete abortion and follow-up in 15 days</span></span></span></p>"
        },
        {
          "id": 23563,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Admit and observe</span></span></span></p>"
        },
        {
          "id": 23564,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diagnostic laparoscopy</span></span></span></p>"
        },
        {
          "id": 23565,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follow-up with beta-HCG</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with 6 weeks amenorrhea and a positive pregnancy test came with complaints of lower abdominal pain, moderate bleeding PV. She was hemodynamically stable. On ultrasound, there was no gestational sac in the uterus. Ovaries were normal and no free fluid in the pouch of Douglas. What is the next line of management?&nbsp;</span></span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q4621660",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769153,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Follow-up with beta-HCG</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient presents with symptoms that could indicate either an ectopic pregnancy or an early miscarriage. The absence of a gestational sac in the uterus on ultrasound at 6 weeks&#39; gestation warrants further investigation to determine the location and viability of the pregnancy. The most appropriate next step is to follow up with serial beta-HCG levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key Points:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ectopic Pregnancy vs. Early Miscarriage:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The differential diagnosis includes both ectopic pregnancy and early miscarriage.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serial Beta-HCG Measurement:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Beta-HCG levels typically double every 48-72 hours in a normal early intrauterine pregnancy. An abnormal rise or plateau in beta-HCG levels may indicate an ectopic pregnancy or a failing pregnancy.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ultrasound Follow-up:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> In combination with beta-HCG monitoring, follow-up ultrasounds can help determine if a gestational sac becomes visible in the uterus or elsewhere.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Declare as complete abortion and follow-up in 15 days:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Declaring a complete abortion without further investigation is premature and may miss an ectopic pregnancy, which can have serious complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Admit and observe:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While observation is important, serial beta-HCG levels provide critical information that can guide further management decisions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Diagnostic laparoscopy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is an invasive procedure and is not the first step in stable patients without definitive evidence of ectopic pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient with 6 weeks of amenorrhea, a positive pregnancy test, and no gestational sac visible on ultrasound, the next step is to follow up with serial beta-HCG levels to differentiate between an early intrauterine pregnancy, an ectopic pregnancy, and a miscarriage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Williams Textbook of obstetrics 24<sup>th </sup>edition pg 356</span></strong></span></span></p>",
      "correct_choice_id": 23565,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6007,
      "choices": [
        {
          "id": 23998,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MgSO<sub>4</sub> causes uterine relaxation, but is dose dependent</span></span></span></p>"
        },
        {
          "id": 23999,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MgSO<sub>4</sub> is continued upto 24 hours after delivery or last attack of seizure</span></span></span></p>"
        },
        {
          "id": 24000,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has inhibitory effect on cerebral cortex thereby preventing seizures and lowering the BP</span></span></span></p>"
        },
        {
          "id": 24001,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In renal failure, MgSO4 loading dose can be given, but maintenance dose should be adjusted based on renal function</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements regarding MgSO<sub>4</sub> is false?&nbsp;</span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q5045549",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769356,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) It has inhibitory effect on cerebral cortex thereby preventing seizures and lowering the BP</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The statement that MgSO4 has an inhibitory effect on the cerebral cortex thereby preventing seizures and lowering the BP is false. MgSO4 is indeed effective in preventing seizures, particularly in the context of eclampsia, due to its action on the cerebral cortex. However, it does not lower blood pressure. Instead, its primary role is as an anticonvulsant and a tocolytic (uterine relaxant), not as an antihypertensive agent. MgSO4&rsquo;s role in managing hypertension is minimal, and it is not used specifically for blood pressure control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. MgSO4 causes uterine relaxation, but is dose dependent:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is true. MgSO4 is used as a tocolytic to relax the uterus in a dose-dependent manner. It helps in managing preterm labor by relaxing uterine contractions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. MgSO4 is continued up to 24 hours after delivery or the last attack of seizure:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is true. Magnesium sulfate is continued for 24 hours after delivery or the last seizure to prevent recurrence of seizures and to provide adequate time for stabilization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. In renal failure, MgSO4 loading dose can be given, but the maintenance dose should be adjusted based on renal function:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is true. In patients with renal failure, the loading dose of MgSO4 can be given, but the maintenance dose should be carefully adjusted due to impaired excretion of magnesium, which could lead to toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MgSO4 is used for preventing seizures in eclampsia and causes uterine relaxation but does not lower blood pressure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 1867, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 24000,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5822,
      "choices": [
        {
          "id": 23258,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligospermia</span></span></span></p>"
        },
        {
          "id": 23259,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teratozoospermia</span></span></span></p>"
        },
        {
          "id": 23260,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asthenozoospermia</span></span></span></p>"
        },
        {
          "id": 23261,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligoasthenoteratozoospermia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The results of semen analysis of a young male have been given below. What is the diagnosis? 5 million/mI concentration, 50% motility, 4% normal morphology?&nbsp;</span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q8540654",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769135,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Oligospermia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given semen analysis results show a sperm concentration of 5 million/mL, which is below the normal reference value set by the WHO. According to the WHO 2021 guidelines, a normal sperm concentration is 16 million/mL or higher. Therefore, this patient has oligospermia, which is defined as a sperm concentration of less than 15 million/mL. Counts below 5 million/mL are considered severe.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key Points:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligospermia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sperm concentration &lt;15 million/mL. Severe oligospermia is when counts are &lt;5 million/mL.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teratozoospermia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Abnormal sperm morphology.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asthenozoospermia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> No motile sperms or diminished motility.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligoasthenoteratozoospermia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A combination of low sperm count, poor motility, and abnormal morphology.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Teratozoospermia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Teratozoospermia refers to abnormal sperm morphology. The morphology here is 4%, which is within the normal range according to WHO criteria.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Asthenozoospermia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Asthenozoospermia refers to reduced sperm motility. In this case, the motility is 50%, which is normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Oligoasthenoteratozoospermia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This term describes a condition where there is a combination of low sperm count, poor motility, and abnormal morphology. In this case, only the sperm concentration is abnormal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligospermia is defined as a sperm concentration of less than 15 million/mL, with counts below 5 million/mL considered severe. The given semen analysis results show oligospermia based on the sperm concentration of 5 million/mL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/02/untitled-289.jpg\" style=\"height:353px; width:900px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of gynecology 3<sup>rd</sup> edition pg 442, Duttas textbook of gynecology 6<sup>th</sup> edition pg232</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><a href=\"https://www.who.int/publications/i/item/9789240030787\" style=\"color:blue; text-decoration:underline\"><strong>https://www.who.int/publications/i/item/9789240030787</strong></a></span></span></p>",
      "correct_choice_id": 23258,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5874,
      "choices": [
        {
          "id": 23466,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malformations</span></span></span></p>"
        },
        {
          "id": 23467,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyhydramnios</span></span></span></p>"
        },
        {
          "id": 23468,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal Macrosomia</span></span></span></p>"
        },
        {
          "id": 23469,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neonatal Hypoglycemia</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the followings are seen in Gestational Diabetes Mellitus except:&nbsp;</span></span></span>(INICET NOV 2019)</p>",
      "unique_key": "Q5655355",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769146,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Malformations</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital malformations are not typically seen with Gestational Diabetes Mellitus (GDM); they are more associated with pre-existing overt diabetes mellitus. When diabetes is present and uncontrolled in the first trimester, particularly with an HbA1C greater than 10%, there is a higher risk of congenital malformations. The most commonly affected system is cardiac, with Ventricular Septal Defect (VSD) being the most common anomaly. A very rare but characteristic anomaly associated with severe diabetes is Mermaid syndrome (sirenomelia).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Polyhydramnios:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Polyhydramnios, characterized by an Amniotic Fluid Index (AFI) greater than 25 or a Single Deepest Pocket (SDP) greater than 8, is common in pregnancies complicated by GDM. It results from increased fetal urination due to hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Fetal Macrosomia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fetal macrosomia, defined as a birth weight greater than 4 kg, is a common complication of GDM. It is associated with excessive fat deposition, particularly around the shoulders, increasing the risk of shoulder dystocia during delivery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Neonatal Hypoglycemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Neonatal hypoglycemia, with blood glucose levels less than 45 mg/dl, is common in infants of mothers with GDM, especially if maternal blood sugar levels were unstable during labor. This occurs because the fetus produces excess insulin in response to maternal hyperglycemia, leading to low blood sugar levels after birth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital anomalies are not typically seen with Gestational Diabetes Mellitus (GDM); they are associated with pre-existing overt diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition pg 2787</span></strong></span></span></p>",
      "correct_choice_id": 23466,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6011,
      "choices": [
        {
          "id": 24014,
          "text": "<p><span style=\"font-size:12pt;\">Lash and Lash cerclage</span></p>"
        },
        {
          "id": 24015,
          "text": "<p><span style=\"font-size:12pt;\">Benson and Durfee cerclage</span></p>"
        },
        {
          "id": 24016,
          "text": "<p><span style=\"font-size:12pt;\">Wurms cerclage</span></p>"
        },
        {
          "id": 24017,
          "text": "<p><span style=\"font-size:12pt;\">Laparoscopic cerclage</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Which of the following cerclage procedures would be done in a nonpregnant female?&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q9293529",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769360,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Lash and Lash cerclage</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Lash and Lash procedure is the only cerclage procedure that is done in the non-pregnant state. Vaginal procedures are preferred over laparoscopic procedure</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Types of Cerclage Procedures (Other Options)</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12pt;\">Transvaginal</span></li><li><span style=\"font-size:12pt;\">Transabdominal</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12pt;\">1. Transvaginal</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">McDonald suture</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Purse string</span></li><li><span style=\"font-size:12pt;\">Below the level of the internal os</span></li><li><span style=\"font-size:12pt;\">Placed during pregnancy (12-14 weeks</span></li><li><span style=\"font-size:12pt;\">Sutures removed at 37 weeks</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/27/untitled-238_O5Ci2Bw.jpg\" alt=\"\" width=\"300\" height=\"283\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Shirodkar cerclage</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Placed during pregnancy (!2-14 weeks)</span></li><li><span style=\"font-size:12pt;\">Bladder pushed up</span></li><li><span style=\"font-size:12pt;\">Closer to internal os</span></li><li><span style=\"font-size:12pt;\">More physiological than McDonald</span></li><li><span style=\"font-size:12pt;\">Usually done if previous failed McDonald</span></li><li><span style=\"font-size:12pt;\">A tape is inserted circumferentially near the os</span></li><li><span style=\"font-size:12.0pt;\">Removed at 37 weeks</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/27/untitled-239.jpg\" alt=\"\" width=\"300\" height=\"280\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Wurm’s Cerclage</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">2 sutures taken as shown in figure</span></li><li><span style=\"font-size:12pt;\">Placed during pregnancy at 12-14 weeks</span></li><li><span style=\"font-size:12.0pt;\">Removed at 37 weeks</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/27/untitled-240.jpg\" alt=\"\" width=\"300\" height=\"344\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Lash Cerclage</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Done PRE-PREGNANCY</span></li><li><span style=\"font-size:12pt;\">A defect in cervix is removed and cervix reconstructed</span></li><li><span style=\"font-size:12pt;\">Deliver is ALWAYS by LSCS</span></li><li><span style=\"font-size:12pt;\">Sutures not removed</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/27/untitled-241.jpg\" alt=\"\" width=\"300\" height=\"296\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">2. Transabdominal:</span></p><p>&nbsp;</p><ol style=\"list-style-type:lower-alpha;\"><li><span style=\"font-size:12pt;\">Could be done by laparotomy (1<sup>st</sup> introduced by Benson and Durfee) OR by Laparoscopy</span></li><li><span style=\"font-size:12pt;\">Preferably done pre-pregnancy but can also be done during pregnancy</span></li><li><span style=\"font-size:12pt;\"><strong>Done in cases of failed transvaginal cerclage procedures.</strong></span></li><li><span style=\"font-size:12pt;\">Most physiological as it is highest (at the level of the cervix)</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Lash and Lash cerclage is the only cerclage procedure done in a nonpregnant female.</span></p>",
      "correct_choice_id": 24014,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InstrumentsBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5877,
      "choices": [
        {
          "id": 23478,
          "text": "<p><span style=\"font-size:12pt;\">4 ml Mgso4 (50% w/v) in 16 ml NS</span></p>"
        },
        {
          "id": 23479,
          "text": "<p><span style=\"font-size:12pt;\">8 ml MgSo4 (50% w/v) in 12 ml NS</span></p>"
        },
        {
          "id": 23480,
          "text": "<p><span style=\"font-size:12pt;\">12 ml MgSo4 (50% w/v) in 8 ml NS</span></p>"
        },
        {
          "id": 23481,
          "text": "<p><span style=\"font-size:12pt;\">10 ml MgSO4 (50% w/v)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The loading dose of MgSo4 in pre-eclampsia is?&nbsp;</span>(INICET NOV 2019)</p>",
      "unique_key": "Q7349135",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769149,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) 8 ml MgSo4 (50% w/v) in 12 ml NS</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The drug of choice for the management of eclampsia is Magnesium Sulfate (MgSO4). The most commonly used regimen in India is the Pritchard regimen, which involves an initial loading dose followed by maintenance doses.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">For the loading dose, the Pritchard regimen recommends:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Loading dose:</strong> 4 grams of MgSO4 as a 20% solution administered intravenously at 1 gram per minute.</span></li><li><span style=\"font-size:12pt;\">Additionally, 10 grams of 50% MgSO4 is administered intramuscularly, with 5 grams in each buttock.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In this question, option B, \"8 ml MgSO4 (50% w/v) in 12 ml NS,\" correctly refers to the preparation required to administer the initial dose of MgSO4.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The preparation details:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">MgSO4 is available in 50% and 20% concentrations.</span></li><li><span style=\"font-size:12pt;\">To make a 50% MgSO4 solution into a 20% solution, a 1.5 times dilution is required.</span></li><li><span style=\"font-size:12pt;\">For a 50% MgSO4 solution, 1 ml of the solution contains 0.5 grams of MgSO4 (1 ampoule = 2 ml).</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The loading dose of MgSO4 in pre-eclampsia, as per the Pritchard regimen, is 4 grams of MgSO4 as a 20% solution administered intravenously, often prepared using 8 ml of 50% MgSO4 diluted in 12 ml normal saline.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Dutta’s textbook of obstetrics 8<sup>th</sup> edition pg273, Williams textbook of obstetrics 24<sup>th</sup> edition pg 1840</strong></span></p>",
      "correct_choice_id": 23479,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5938,
      "choices": [
        {
          "id": 23722,
          "text": "<p><span style=\"font-size:12.0pt;\">Misoprostol 400 mcg</span></p>"
        },
        {
          "id": 23723,
          "text": "<p><span style=\"font-size:12.0pt;\">Ethinyl estradiol 600 mcg</span></p>"
        },
        {
          "id": 23724,
          "text": "<p><span style=\"font-size:12.0pt;\">Ulipristal 30 mg</span></p>"
        },
        {
          "id": 23725,
          "text": "<p><span style=\"font-size:12.0pt;\">Levonorgestrel 1.5 mg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following emergency contraceptive is used in India?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q8681401",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769342,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Levonorgestrel 1.5 mg</strong></span></p><p><br><span style=\"font-size:12.0pt;\">In India, <strong>Levonorgestrel 1.5 mg</strong> is commonly used as an emergency contraceptive. This medication is effective when taken within 72 hours of unprotected intercourse. It works primarily by inhibiting or delaying ovulation, thus preventing pregnancy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/26/untitled-228.jpg\" alt=\"\" width=\"900\" height=\"311\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Misoprostol 400 mcg:</strong> Incorrect. Misoprostol is used for medical abortion and does not serve as an emergency contraceptive.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Ethinyl estradiol 600 mcg:</strong> Incorrect. Ethinyl estradiol is used in combined oral contraceptive pills, but it is not commonly used alone for emergency contraception. The Yuzpe regimen, which includes ethynyl estradiol, is less commonly used compared to levonorgestrel.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Ulipristal 30 mg:</strong> Incorrect. Ulipristal acetate (30 mg) is a selective progesterone receptor modulator used as an emergency contraceptive, but it is not as widely available or commonly used in India as levonorgestrel.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Levonorgestrel 1.5 mg is the emergency contraceptive used in India.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 243, Berek and Novak’s Gynecology 15<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23725,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20500,
      "choices": [
        {
          "id": 81962,
          "text": "<p><span style=\"font-size:12pt;\">G3P2</span></p>"
        },
        {
          "id": 81963,
          "text": "<p><span style=\"font-size:12pt;\">G3P1</span></p>"
        },
        {
          "id": 81964,
          "text": "<p><span style=\"font-size:12pt;\">G2P1</span></p>"
        },
        {
          "id": 81965,
          "text": "<p><span style=\"font-size:12pt;\">G2P2</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A pregnant woman comes to the clinic. She already has twins by normal delivery. Which of the following is the correct representation of her obstetric score?&nbsp;</span>(NEET PG 2023)</p>",
      "unique_key": "Q8910790",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769368,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) G2P1</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In obstetric history, gravida (G) refers to the number of pregnancies a woman has had, including the current pregnancy, regardless of the outcome or duration. Parity (P) refers to the number of pregnancies that have reached the period of viability (28 weeks in India). Each pregnancy is counted once, regardless of the number of fetuses (e.g., twins count as one pregnancy).</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Gravida (G):</strong> Number of pregnancies, including the current one.</span></li><li><span style=\"font-size:12pt;\"><strong>Parity (P):</strong> Number of pregnancies that have reached viability (28 weeks or more), not including the current pregnancy.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In this case:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">The woman has had one previous pregnancy that resulted in the birth of twins.</span></li><li><span style=\"font-size:12pt;\">She is currently pregnant with her second pregnancy.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Therefore, her obstetric score is:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>G2 (Gravida 2):</strong> This is her second pregnancy.</span></li><li><span style=\"font-size:12pt;\"><strong>P1 (Para 1):</strong> She has had one previous pregnancy that reached viability and resulted in the birth of twins.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. G3P2:</strong> This would imply she has had three pregnancies and two that reached viability, which is incorrect.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. G3P1:</strong> This would imply she is in her third pregnancy, which is incorrect.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. G2P2:</strong> This would imply she has had two previous pregnancies that reached viability, which is incorrect.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In obstetric scoring, twin pregnancies count as a single gravida, and the obstetric score for a woman with twins by normal delivery and currently pregnant should be G2P1.</span></p>",
      "correct_choice_id": 81964,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6025,
      "choices": [
        {
          "id": 24070,
          "text": "<p><span style=\"font-size:12pt;\">NST and fetal tone</span></p>"
        },
        {
          "id": 24071,
          "text": "<p><span style=\"font-size:12pt;\">NST and AFI</span></p>"
        },
        {
          "id": 24072,
          "text": "<p><span style=\"font-size:12pt;\">NST and breathing movements</span></p>"
        },
        {
          "id": 24073,
          "text": "<p><span style=\"font-size:12pt;\">NST and gross fetal movements</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Modified biophysical profile includes?&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q7546537",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769366,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) NST and AFI</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Modified Biophysical Profile (BPP) includes two key components: the Non-Stress Test (NST) and the Amniotic Fluid Index (AFI). This abbreviated version of the BPP focuses on assessing fetal well-being through these two measures. The NST evaluates fetal heart rate patterns in response to fetal movements, while the AFI assesses the amount of amniotic fluid, which can indicate the health of the placenta and overall fetal condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. NST and fetal tone:</strong> This combination is not the Modified BPP. While the NST is part of the Modified BPP, fetal tone is part of the complete Biophysical Profile but not included in the Modified BPP.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. NST and breathing movements</strong>: Breathing movements are part of the complete Biophysical Profile, but not included in the Modified BPP, which only uses NST and AFI.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. NST and gross fetal movements</strong>: Gross fetal movements are part of the full Biophysical Profile, but not included in the Modified BPP, which comprises only NST and AFI.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Modified Biophysical Profile (BPP) includes the Non-Stress Test (NST) and the Amniotic Fluid Index (AFI).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 980, Williams Obstetrics 26<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 24071,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6006,
      "choices": [
        {
          "id": 23994,
          "text": "<p><span style=\"font-size:12pt;\">Elective C-section has no role in reducing incidence of brachial plexus injury</span></p>"
        },
        {
          "id": 23995,
          "text": "<p><span style=\"font-size:12pt;\">In a patient being planned for induction of labor, night dose of intermediate insulin is given as planned, and the morning dose is withheld</span></p>"
        },
        {
          "id": 23996,
          "text": "<p><span style=\"font-size:12pt;\">In active labor, if RBS &lt;70 mg%, D5 is started at 100-150 ml/h till the RBS is &gt;100 mg%</span></p>"
        },
        {
          "id": 23997,
          "text": "<p><span style=\"font-size:12pt;\">Capillary blood glucose monitoring levels are kept at fasting- 95 mg%; 1 h postprandial- 140 mg%; 2 h postprandial: 120 mg%</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is false regarding management of diabetes in pregnancy?&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q6509098",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769355,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Elective C-section has no role in reducing incidence of brachial plexus injury</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">False statement regarding management of diabetes in pregnancy is option A.</span></li><li><span style=\"font-size:12pt;\">The Cesarean section is found to be protective against traumatic injuries such as brachial plexus injury, in macrosomic babies born to mothers with diabetes.</span></li><li><span style=\"font-size:12pt;\">Elective LSCS is recommended when the estimated fetal weight is &gt; 4.5kg in diabetic mothers to reduce the incidence of birth trauma</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. In a patient being planned for induction of labor, night dose of intermediate insulin is given as planned, and the morning dose is withheld</strong>: In a planned delivery, although the bedtime dose of intermediate-acting insulin is given, it is recommended that the morning dose must be withheld</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Insulin Management for Labor Induction or Scheduled Cesarean Delivery</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/27/untitled-236.jpg\" alt=\"\" width=\"900\" height=\"271\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. In active labor, if RBS &lt;70 mg%, D5 is started at 100-150 ml/h till the RBS is &gt;100 mg%:</strong> In active labor, if RBS (Random blood glucose) &lt;70 mg%, D5 (5% dextrose) is started at 100-150 ml/h till the RBS is &gt;100 mg%. Before initiation of labor, normal saline is used for iv infusion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Capillary blood glucose monitoring levels are kept at fasting- 95 mg%; 1 h postprandial- 140 mg%; 2 h postprandial: 120 mg%:</strong> Self-monitoring of capillary blood glucose is advised in a pregnant woman diagnosed with diabetes. The glucose goals recommended are:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Fasting: 95 mg/dL</strong></span></li><li><span style=\"font-size:12pt;\"><strong>1 h postprandial: 140 mg/dL</strong></span></li><li><span style=\"font-size:12pt;\"><strong>2 h postprandial: 120 mg/dL</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Elective C-section can reduce the incidence of brachial plexus injury in pregnancies complicated by diabetes, especially in cases of fetal macrosomia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 2807, Williams Obstetrics 26<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23994,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5824,
      "choices": [
        {
          "id": 23266,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha fetoprotein</span></span></span></p>"
        },
        {
          "id": 23267,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta HCG</span></span></span></p>"
        },
        {
          "id": 23268,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal fibronectin</span></span></span></p>"
        },
        {
          "id": 23269,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PAPP-A</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A woman with 31 weeks of gestation presents with lower abdominal pain. The clinician is concerned if the patient is in preterm labor. Which of the following is the most appropriate test in this scenario?&nbsp;</span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q2964478",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769137,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Fetal fibronectin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal fibronectin (fFN) is a glycoprotein produced by fetal amnion cells and found in high concentrations in amniotic fluid. It is also found in cervico-vaginal secretions in early pregnancy (less than 22 weeks) and late pregnancy (greater than 37 weeks). The presence of fFN in cervico-vaginal secretions between 22 and 37 weeks is used as a predictor of preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A fFN level greater than 50 ng/mL is considered a significant predictor of preterm labor. The American College of Obstetricians and Gynecologists (ACOG) does not recommend routine use of fFN testing but it can be helpful in specific clinical scenarios where preterm labor is suspected.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Alpha fetoprotein:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Alpha fetoprotein (AFP) is used in prenatal screening for neural tube defects and as a component of the quadruple marker test for Down syndrome. Elevated AFP levels are associated with neural tube defects, while decreased levels can indicate Down syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Beta HCG:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Beta HCG is used in early pregnancy for confirming pregnancy and in first trimester screening for Down syndrome (where levels are elevated). It is not used for diagnosing preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. PAPP-A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Pregnancy-associated plasma protein-A (PAPP-A) is used in first trimester screening for Down syndrome, where its levels are decreased. It is not used for diagnosing preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal fibronectin (fFN) testing is the most appropriate test for assessing the risk of preterm labor in a woman presenting with lower abdominal pain at 31 weeks of gestation. A positive fFN test (greater than 50 ng/mL) can help predict the likelihood of preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg 366</span></strong></span></span></p>",
      "correct_choice_id": 23268,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6024,
      "choices": [
        {
          "id": 24066,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary syphilis</span></span></span></p>"
        },
        {
          "id": 24067,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital syphilis</span></span></span></p>"
        },
        {
          "id": 24068,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Secondary syphilis</span></span></span></p>"
        },
        {
          "id": 24069,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Latent syphilis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kassowitz rule is related to?&nbsp;</span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q7438783",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769365,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Congenital syphilis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kassowitz&#39;s rule pertains to congenital syphilis. According to this rule, if a woman with untreated syphilis has multiple pregnancies, the likelihood of congenital syphilis affecting the fetus in later pregnancies decreases. This phenomenon is observed as a result of the immune system&#39;s adaptive response and potential changes in the transmission dynamics of the infection over successive pregnancies. Therefore, the rule suggests that with each subsequent pregnancy, the outcome for the fetus improves if the infection remains untreated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Primary syphilis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Primary syphilis involves the initial chancre or ulcer at the site of infection and is not related to Kassowitz&#39;s rule, which specifically addresses outcomes in congenital syphilis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Secondary syphilis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Secondary syphilis is characterized by systemic manifestations such as skin rashes and mucous membrane lesions and is not related to Kassowitz&#39;s rule.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Latent syphilis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Latent syphilis refers to a stage where no symptoms are present but the infection is still systemic. Kassowitz&#39;s rule is not associated with latent syphilis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kassowitz rule states that the likelihood of congenital syphilis infection decreases with each successive pregnancy in a woman with untreated syphilis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 343, DC Dutta&rsquo;s Textbook of Obstetrics 8<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 24067,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5932,
      "choices": [
        {
          "id": 23698,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum FSH levels</span></p>"
        },
        {
          "id": 23699,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum testosterone levels</span></p>"
        },
        {
          "id": 23700,
          "text": "<p><span style=\"font-size:12.0pt;\">Testicular Biopsy</span></p>"
        },
        {
          "id": 23701,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum LH level</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A couple presents to the infertility clinic with a normal hysterosalpingogram and a semen analysis report with azoospermia. Which of the following test is useful to differentiate between an obstructive and a testicular cause?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q9527620",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769168,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Testicular Biopsy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The absence of sperm in semen is known as azoospermia. It can be due to:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12.0pt;\">Pre-testicular azoospermia due to a hypothalamic or pituitary abnormality (hypogonadotropic hypogonadism)</span></li><li><span style=\"font-size:12.0pt;\">Testicular failure or non-obstructive azoospermia</span></li><li><span style=\"font-size:12.0pt;\">Post-testicular obstruction implies normal spermatogenesis but failure to deliver the sperm into the ejaculate because of ducal obstruction.</span></li></ul></li><li><span style=\"font-size:12.0pt;\">In testicular cause of azoospermia, there will be absent or very few sperms on biopsy whereas in obstructive azoospermia, there will be normal sperms on biopsy</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Serum FSH levels&nbsp;</strong>and <strong>Option B. Serum testosterone levels</strong> are important for spermatogenesis</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">FSH levels can be used to differentiate hypogonadotrophic hypogonadism from other causes of testicular failure</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Serum LH level</strong>: LH is a non-specific test in evaluation of azoospermia</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A testicular biopsy is useful to differentiate between an obstructive and a testicular cause of Azoospermia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 233, DC Dutta’s Textbook of Gynecology 6the edition</strong></span></p>",
      "correct_choice_id": 23700,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5893,
      "choices": [
        {
          "id": 23542,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibit implantation</span></span></span></p>"
        },
        {
          "id": 23543,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cervical mucus thickening</span></span></span></p>"
        },
        {
          "id": 23544,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibit ovulation</span></span></span></p>"
        },
        {
          "id": 23545,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase GnRH release</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral contraceptives act by all of the following mechanisms except:&nbsp;</span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q6471954",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769151,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Increase GnRH release</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral contraceptive pills (OCPs) function through several mechanisms to prevent pregnancy, but increasing the release of Gonadotropin-Releasing Hormone (GnRH) is not one of them. In fact, OCPs inhibit the release of GnRH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanisms of action of OCPs:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibit ovulation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> By suppressing the release of GnRH, and consequently, the pituitary secretion of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH), OCPs prevent the development and release of an ovum.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prevent implantation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs create a less favorable endometrial environment for implantation of a fertilized egg.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cervical mucus thickening:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs increase the viscosity of cervical mucus, making it more difficult for sperm to enter the uterus and fertilize an ovum.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Produce static endometrial hypoplasia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs cause the endometrial lining to remain thin, which further prevents implantation.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Affect tubal motility:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs can alter the motility of the fallopian tubes, reducing the likelihood of sperm meeting an ovum.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Inhibit implantation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs prevent the endometrium from becoming suitable for implantation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Cervical mucus thickening:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs increase the thickness of cervical mucus to block sperm penetration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Inhibit ovulation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs suppress the hormonal signals that trigger ovulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral contraceptive pills prevent pregnancy by inhibiting ovulation, preventing implantation, thickening cervical mucus, producing static endometrial hypoplasia, and affecting tubal motility. They do not increase GnRH release; rather, they inhibit it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of Gynecology 6<sup>th</sup> edition 485</span></strong></span></span></p>",
      "correct_choice_id": 23545,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5957,
      "choices": [
        {
          "id": 23798,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1 and 3 only</span></span></span></p>"
        },
        {
          "id": 23799,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1 and 2 only</span></span></span></p>"
        },
        {
          "id": 23800,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">2 and 3 only</span></span></span></p>"
        },
        {
          "id": 23801,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1 and 4 only</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following modalities are used for the diagnosis of placenta accreta?&nbsp;</span></span></span>(INICET MAY 2021)</p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ultrasonography</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">MRI</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Angiography</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">X-ray</span></span></span></li>\r\n</ol>",
      "unique_key": "Q1919265",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769351,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) 1 and 2 only</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ultrasonography and MRI are key modalities used in the diagnosis of placenta accreta.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ultrasonography (1)</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This is often the first imaging modality used to diagnose placenta accreta. It helps in visualizing the placental attachment and identifying abnormalities in placental implantation. Color Doppler ultrasonography is particularly useful to assess the blood flow and the vascularity of the placenta, which can indicate abnormal adherence.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">MRI (2)</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: MRI is used as a complementary imaging tool when ultrasonography results are inconclusive or to provide a more detailed view. It helps in evaluating the depth of placental invasion into the myometrium and can differentiate between placenta accreta, increta, and percreta.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Angiography (3)</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: While angiography can provide information about blood vessels and may be used in some cases to evaluate blood flow abnormalities, it is not typically a primary diagnostic tool for placenta accreta. It may be used in specific scenarios or to plan surgical management, but it is not generally used for initial diagnosis.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">X-ray (4)</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: X-rays are not used in the diagnosis of placenta accreta due to their lack of sensitivity for soft tissue detail and the potential risk to the fetus. X-rays are not helpful in visualizing the placenta or its adherence to the uterine wall.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Incorrect because it includes Angiography, which is not commonly used for the initial diagnosis of placenta accreta.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Incorrect because it includes Angiography, which is not a primary diagnostic tool for placenta accreta, and it excludes Ultrasonography, which is crucial for diagnosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Incorrect because X-ray is not used for diagnosing placenta accreta and does not contribute to the diagnosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ultrasonography and MRI are the primary modalities used for diagnosing placenta accreta.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 1982, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23799,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6009,
      "choices": [
        {
          "id": 24006,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostaglandins play an important role. Thromboxane A2 decreases; Prostacyclin: Thromboxane ratio increases in preeclampsia</span></span></span></p>"
        },
        {
          "id": 24007,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endothelial cell dysfunction leads to reduced nitric oxide levels and this causes the clinical presentation of preeclampsia</span></span></span></p>"
        },
        {
          "id": 24008,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vasoconstriction leads to ischemia, necrosis and hemorrhage and end organ damage seen in preeclampsia</span></span></span></p>"
        },
        {
          "id": 24009,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-angiogenic factors play an important role in preeclampsia. There is an increase in FIt-1 and decrease in PIGF</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are theories of causation of preeclampsia except:&nbsp;</span></span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q6263408",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769358,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Prostaglandins play an important role. Thromboxane A2 decreases; Prostacyclin: Thromboxane ratio increases in preeclampsia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are theories of causation of preeclampsia except option A. There is reduced or absent prostacyclin (PGI,) production with increased production of thromboxane (TXA,) and reduced ratio of prostacyclin: thromboxane in preeclampsia.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Endothelial cell dysfunction leads to reduced nitric oxide levels and this causes the clinical presentation of preeclampsia:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endothelial cell dysfunction is another etiology. Injured or activated endothelial cells may produce less nitric oxide and may secrete substances that promote coagulation and vasopressor sensitivity. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Vasoconstriction leads to ischemia, necrosis and hemorrhage and end organ damage seen in preeclampsia:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vasospasm has long been associated with preeclampsia. Systemic endothelial activation causes vasospasm, which elevates resistance to produce hypertension. With diminished blood flow because of maldistribution from vasospasm and interstitial leakage, ischemia of the surrounding tissues can cause necrosis, hemorrhage, and other end-organ disturbances. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Anti-angiogenic factors play an important role in preeclampsia. There is an increase in FIt-1 and decrease in PIGF:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Angiogenic Factors: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placental vasculogenesis is evident 21 days after conception. Two antiangiogenic peptides that are increased</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Soluble fms-like tyrosine kinase 1 (s-flt-1)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Soluble endoglin (s-eng)</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Factors that are decreased are</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PlGF</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PAPP-A</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VEGF</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/27/untitled-237.jpg\" style=\"height:407px; width:500px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In preeclampsia, the prostacyclin: thromboxane ratio is decreased due to increased thromboxane A2 and decreased prostacyclin (PGI2).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 1802, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 24006,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5947,
      "choices": [
        {
          "id": 23758,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Epithelial cell tumor</span></span></span></p>"
        },
        {
          "id": 23759,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Germ cell tumor</span></span></span></p>"
        },
        {
          "id": 23760,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sex cord stromal tumor</span></span></span></p>"
        },
        {
          "id": 23761,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Granulosa cell tumor</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which class of ovarian tumor does clear cell carcinoma of the ovary belong to?&nbsp;</span></span></span>(INICET MAY 2021)</p>",
      "unique_key": "Q4952342",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769344,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Epithelial cell tumor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Clear cell carcinoma of the ovary</strong> is classified under epithelial cell tumors. Epithelial ovarian tumors originate from the cells that line the surface of the ovary. Clear cell carcinoma is a subtype of epithelial ovarian tumors.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Classification of ovarian tumors:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Epithelial Cell Tumor</span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Serous</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Mucinous</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Brenner</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clear cell</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Endometrioid</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clear cell carcinoma</span></strong><span style=\"font-size:12.0pt\"> falls under this category.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Germ Cell Tumor</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Dysgerminoma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Yolk sac tumor</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Choriocarcinoma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Teratoma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Embryonal</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clear cell carcinoma</span></strong><span style=\"font-size:12.0pt\"> is not classified here.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Sex Cord Stromal Tumor</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Granulosa cell tumor</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Thecoma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Fibroma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Sertoli-Leydig cell tumor</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clear cell carcinoma</span></strong><span style=\"font-size:12.0pt\"> is not included in this category.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ol>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clear cell carcinoma of the ovary is classified as an epithelial cell tumor.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 291, DC Dutta&rsquo;s Textbook of Gynecology 6<sup>th</sup> edition </span></strong></span></span></p>",
      "correct_choice_id": 23758,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5866,
      "choices": [
        {
          "id": 23434,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">MgSO4</span></span></span></p>"
        },
        {
          "id": 23435,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nifedipine</span></span></span></p>"
        },
        {
          "id": 23436,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ritoridine</span></span></span></p>"
        },
        {
          "id": 23437,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isoxsuprine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In preterm labor which drug has a neuro-protective role? (AIIMS NOV 2019)</span></span></p>",
      "unique_key": "Q1054114",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769142,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) MgSO4</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neuroprotection in preterm labor:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The drug given is MgSO4.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It reduces the incidence of cerebral palsy and neurodevelopmental delay.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV MgSO4 should be offered for neuroprotection of the baby to all women between 24+0 and 29+6 weeks who are:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In established preterm labor or</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Having a planned preterm birth within 24 hours.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be considered for neuroprotection of the baby for women between 30+0 and 33+6 weeks.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dose:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> 4 g intravenous bolus of magnesium sulfate over 15 minutes, followed by an intravenous infusion of 1 g per hour until the birth or for 24 hours (whichever is sooner).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uses of MgSO4 in Obstetrics:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of Eclampsia (Anti-seizure)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prophylaxis in severe pre-eclampsia (to prevent eclampsia)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As a tocolytic in preterm labor</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As a neuroprotective drug in preterm labor (especially &lt; 30 weeks)</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Nifedipine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A calcium channel blocker used as a tocolytic and antihypertensive but has no role in neuroprotection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ritodrine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A beta-sympathomimetic used as a tocolytic but has no neuroprotective role.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Isoxsuprine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Another beta-sympathomimetic used as a tocolytic without neuroprotective properties.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In preterm labor, MgSO4 is used for neuroprotection, reducing the incidence of cerebral palsy and neurodevelopmental delay in preterm infants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition, Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg 538</span></strong></span></span></p>",
      "correct_choice_id": 23434,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5896,
      "choices": [
        {
          "id": 23554,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hysterectomy</span></span></span></p>"
        },
        {
          "id": 23555,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conization</span></span></span></p>"
        },
        {
          "id": 23556,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Colposcopy and biopsy</span></span></span></p>"
        },
        {
          "id": 23557,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follow-up after 6 months</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman is diagnosed with carcinoma in situ (CIS) of the cervix and no obvious macroscopic growth. What is the next line of management?&nbsp;</span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q7289097",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769152,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Conization</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carcinoma in situ is Stage 0 Cancer. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It means it involves the entire thickness of the epithelium without invasion of the basement membrane. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This should be followed by a conization as the woman is 30 years old and conization will provide us with a biopsy specimen as well as be curative</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If family is complete/ elderly patient, simple hysterectomy should be done</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment for Different stages of cervical cancer </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/30/untitled-278.jpg\" style=\"height:396px; width:900px\" /></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hysterectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While effective, it is more invasive and typically reserved for those who have completed childbearing or for older patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Colposcopy and biopsy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is used for further evaluation but is not the definitive treatment for CIS when the diagnosis is already confirmed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Follow-up after 6 months:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Follow-up without intervention is not appropriate for CIS due to the risk of progression to invasive cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a young woman diagnosed with carcinoma in situ (CIS) of the cervix, conization is the recommended next step, providing both diagnostic and therapeutic benefits.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: FIGO Revised Staging of Cervical Cancer, Berek and Novak&rsquo;s Gynecology 15<sup>th</sup> Edition, Dutta&rsquo;s textbook of Gynecology 8<sup>th</sup> edition page367, </span></strong></span></span></p>",
      "correct_choice_id": 23555,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5815,
      "choices": [
        {
          "id": 23230,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unmotivated patient</span></span></span></p>"
        },
        {
          "id": 23231,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Menorrhagia</span></span></span></p>"
        },
        {
          "id": 23232,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous ectopic pregnancy</span></span></span></p>"
        },
        {
          "id": 23233,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous history of abortion</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following would be considered as an absolute contraindication for insertion of copper T to a patient?&nbsp;</span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q3361062",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769128,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Unmotivated patient</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inserting a copper T intrauterine device (IUD) requires the patient to be motivated and consent to the procedure. An unmotivated patient or one who does not consent should never undergo the procedure. This is because the successful use of an IUD requires patient understanding, willingness to comply with follow-up care, and adherence to guidelines for managing any potential side effects or complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absolute contraindications for the use of copper IUDs include:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unexplained uterine or vaginal bleeding</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post-abortal sepsis, puerperal sepsis, current pelvic inflammatory disease (PID), or genital tuberculosis</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cancers such as endometrial cancer, cervical cancer, and gestational trophoblastic neoplasia</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Large fibroids distorting the uterine cavity or Mullerian anomalies distorting the uterine cavity</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Menorrhagia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While menorrhagia is a relative contraindication, as the copper IUD can exacerbate heavy menstrual bleeding, it is not an absolute contraindication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Previous ectopic pregnancy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A history of ectopic pregnancy is a consideration but not an absolute contraindication for copper IUD use.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Previous history of abortion:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A previous history of abortion is not an absolute contraindication for the insertion of a copper IUD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An unmotivated patient or one who does not consent is an absolute contraindication for the insertion of a copper T intrauterine device (IUD).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of gynecology 6th edition pg 480</span></strong></span></span></p>",
      "correct_choice_id": 23230,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5868,
      "choices": [
        {
          "id": 23442,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Minute volume decreases by 50%</span></span></span></p>"
        },
        {
          "id": 23443,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Residual volume increases</span></span></span></p>"
        },
        {
          "id": 23444,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FRC decreases</span></span></span></p>"
        },
        {
          "id": 23445,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total lung capacity increases</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The correct statement regarding the physiological changes in the respiratory system in pregnancy?&nbsp;</span></span>(INICET NOV 2019)</p>",
      "unique_key": "Q2133632",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769143,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) FRC decreases</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/30/untitled-277.jpg\" style=\"height:644px; width:900px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Minute volume decreases by 50%:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is incorrect. In fact, minute ventilation, which is the total volume of air inspired in a minute, increases by 40% during pregnancy due to an increase in tidal volume.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Residual volume increases:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is incorrect. Residual volume, which is the volume of air remaining in the lungs after maximal expiration, decreases by 20-25% during pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Total lung capacity increases:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is incorrect. Total lung capacity, which is the maximum amount of air the lungs can hold, is either unaffected or slightly decreased (by about 5%) during pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Functional Residual Capacity (FRC) decreases by approximately 22% during pregnancy due to the upward displacement of the diaphragm by the enlarging uterus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition pg189, Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg 6</span></strong></span></span></p>",
      "correct_choice_id": 23444,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5870,
      "choices": [
        {
          "id": 23450,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">APLA syndrome</span></span></span></p>"
        },
        {
          "id": 23451,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital heart defects</span></span></span></p>"
        },
        {
          "id": 23452,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SLE</span></span></span></p>"
        },
        {
          "id": 23453,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemolytic anemia</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">On finding a congenital heart block in a fetus which of the following conditions would you evaluate for in the mother?&nbsp;</span></span>(INICET NOV 2019)</p>",
      "unique_key": "Q6419106",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769144,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) SLE</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital heart block (CHB) in a fetus is often associated with maternal autoimmune conditions, particularly Systemic Lupus Erythematosus (SLE). This condition is related to the presence of maternal antibodies against the SS-A (Ro) or SS-B (La) antigens. These antibodies can cross the placenta and affect the fetal heart, leading to congenital heart block. Therefore, if a congenital heart block is detected in a fetus, it is essential to evaluate the mother for SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neonatal lupus erythematosus, a subtype of lupus erythematosus, is caused by the transplacental passage of these maternal antibodies. The most frequent clinical manifestations in the neonate include congenital heart block and cutaneous lesions. Fetal echocardiography is recommended between 18 and 26 weeks of gestation in pregnancies where these antibodies are present to monitor for congenital heart block.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. APLA syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Antiphospholipid antibody syndrome (APLA) is associated with increased risks of miscarriages, intrauterine fetal demise (IUFD), and preterm births. However, it is not specifically associated with congenital heart block in the fetus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Congenital heart defects:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Women with certain congenital cardiac defects may have an increased chance of giving birth to children with similar defects, such as Marfan syndrome, aortic stenosis, ventricular septal defect (VSD), atrial septal defect (ASD), and coarctation of the aorta. However, these conditions are not directly linked to congenital heart block caused by maternal antibodies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hemolytic anemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hemolytic anemias, such as thalassemia, sickle cell anemia, and hereditary spherocytosis, are inherited conditions but are not associated with congenital heart block in the fetus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital heart block (CHB) in a fetus is associated with maternal antibodies to SS-A (Ro) or SS-B (La), commonly seen in Systemic Lupus Erythematosus (SLE).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg 722</span></strong></span></span></p>",
      "correct_choice_id": 23452,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5819,
      "choices": [
        {
          "id": 23246,
          "text": "<p><span style=\"font-size:12pt;\">Stop the surgery</span></p>"
        },
        {
          "id": 23247,
          "text": "<p><span style=\"font-size:12pt;\">Change the fluid to normal saline</span></p>"
        },
        {
          "id": 23248,
          "text": "<p><span style=\"font-size:12pt;\">Continue the surgery with careful monitoring of fluid status</span></p>"
        },
        {
          "id": 23249,
          "text": "<p><span style=\"font-size:12pt;\">Give furosemide to the patient and continue surgery</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25-year-old lady with submucosal fibroid was undergoing myomectomy. The surgeon was using 1.5% glycine as irrigating fluid for the cavity. During the surgery, the nurse informs that there is a 500ml deficit of the irrigating fluid. What is the next step to be done?&nbsp;</span>(INICET NOV 2018)</p>",
      "unique_key": "Q7245550",
      "question_audio": null,
      "question_video": null,
      "map_id": 32769132,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) Continue the surgery with careful monitoring of fluid status</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">During hysteroscopy, systemic absorption of uterine distension fluid occurs through open sinuses or vessels. Increased fluid absorption is seen with higher intrauterine pressure, longer procedure duration, deep myometrial penetration, and a large uterus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Excessive absorption of hypotonic electrolyte-free fluids, such as 1.5% glycine, can cause hypo-osmolality, hyponatremia, cerebral edema, hypotonic encephalopathy, permanent neurologic injury, heart failure, pulmonary edema, and death. However, in this case, the fluid deficit is 500 mL, which is within the allowable limits for a healthy patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Fluid Management Guidelines:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Hypotonic solutions (e.g., 1.5% glycine):</strong> The maximum allowed fluid deficit is 1000 mL for healthy patients and 750 mL for elderly patients or those with medical comorbidities.</span></li><li><span style=\"font-size:12pt;\"><strong>Normal saline:</strong> The maximum allowed fluid deficit is 2500 mL for healthy patients and 750 mL for those with cardiovascular disease.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Fluid absorption can be reduced by:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Pre-operative treatment with GnRH agonists.</span></li><li><span style=\"font-size:12pt;\">Intraoperative injection of dilute vasopressin (0.05 U/mL).</span></li><li><span style=\"font-size:12pt;\">Using the lowest intrauterine pressure that provides adequate visualization, ensuring it is below the mean arterial pressure.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Management of fluid overload:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Hypotonic fluid overload:</strong> Obtain serum electrolytes and evaluate the patient for volume overload. Asymptomatic hyponatremia can be treated with fluid restriction and careful monitoring of urine output. Symptomatic hyponatremia requires infusion of 3% sodium chloride and management in intensive care.</span></li><li><span style=\"font-size:12pt;\"><strong>Normal saline overload:</strong> Managed by fluid restriction; IV furosemide (20-40 mg) is indicated if there is clinical or radiological evidence of pulmonary edema.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options :</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Stop the surgery:</strong> This is not necessary at a fluid deficit of 500 mL, as it is within the safe limit for a healthy patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Change the fluid to normal saline:</strong> While normal saline can be used, it is not required to change the fluid type mid-procedure unless there are signs of significant complications or excessive fluid absorption.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Give furosemide to the patient and continue surgery:</strong> Furosemide is indicated if there is evidence of fluid overload or pulmonary edema, which is not the case here with a 500 mL deficit.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In the context of a 500 mL fluid deficit during hysteroscopy with 1.5% glycine as the irrigating fluid, it is appropriate to continue the surgery with car</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: William’s textbook of gynecology 3<sup>rd</sup> edition pg903</strong></span></p>",
      "correct_choice_id": 23248,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}